University of Tennessee Health Science Center

UTHSC Digital Commons
Theses and Dissertations (ETD)

College of Graduate Health Sciences

5-2012

The Molecular Basis of Fitness and Transmissibility of
Neuraminidase Inhibitor Resistant Influenza A Viruses
Susu Duan
University of Tennessee Health Science Center

Follow this and additional works at: https://dc.uthsc.edu/dissertations
Part of the Enzymes and Coenzymes Commons, Medical Immunology Commons, Medical
Microbiology Commons, Medical Molecular Biology Commons, and the Virus Diseases Commons

Recommended Citation
Duan, Susu , "The Molecular Basis of Fitness and Transmissibility of Neuraminidase Inhibitor Resistant
Influenza A Viruses" (2012). Theses and Dissertations (ETD). Paper 62. http://dx.doi.org/10.21007/
etd.cghs.2012.0074.

This Dissertation is brought to you for free and open access by the College of Graduate Health Sciences at UTHSC
Digital Commons. It has been accepted for inclusion in Theses and Dissertations (ETD) by an authorized
administrator of UTHSC Digital Commons. For more information, please contact jwelch30@uthsc.edu.

The Molecular Basis of Fitness and Transmissibility of Neuraminidase Inhibitor
Resistant Influenza A Viruses
Abstract
Neuraminidase (NA) inhibitors including oral oseltamivir and inhaled zanamivir are among the first line of
defense against influenza virus infection. Development of resistance to NA inhibitors is a huge drawback
for limited options for the control of influenza. During the first decade of NA inhibitor use, the detection
rates of resistance to both NA inhibitors had remained low in circulating influenza viruses. However, the
2008~2009 season was marked by a radical increase of prevalence of oseltamvir resistance from <1% to
>90% in worldwide surveillance in less than a year. The resistance was solely linked to NA H275Y variants
of seasonal H1N1 viruses, and they are referred as the naturally resistant viruses. A big question remains
open about what fundamental molecular changes in the seasonal H1N1 viruses led to the surge of the
naturally resistant viruses. When this question remained pending, a novel swine-origin H1N1 influenza
virus emerged in Mexico at April 2009, soon spread worldwide replacing the seasonal influenza viruses
including the naturally resistant viruses, and marked 2009 with the first influenza pandemic of the 21st
century. With sustainably increased worldwide use of NA inhibitors especially oral oseltamivir during the
pandemic, the oseltamivir-resistant variants carrying H275Y NA mutation were isolated at low incidence
from individuals receiving oseltamivir treatment and a few community clusters. In view of the high
prevalence of naturally resistant seasonal H1N1 viruses in the immediate preceding season, there was an
urgent need to characterize the transmissibility and fitness of oseltamivir-resistant pandemic H1N1/2009
viruses, although the resistance rates have remained low so far.
We first addressed the urgent question about pandemic viruses by investigating the transmissibility of a
closely matched pair of pandemic H1N1/2009 clinical isolates, which only differed at the H275Y NA
mutation in their genome, in the ferret model. We found that the H275Y NA mutant H1N1/2009 virus was
not transmitted efficiently in ferrets via respiratory droplets, while it retained efficient transmission via
direct contact. The wild-type H1N1/2009 virus was efficiently transmitted via both routes. The wild-type
and the mutant viruses appeared to cause a similar disease course in ferrets without apparent
attenuation of clinical signs. In the growth competition in a ferret, the H275Y mutant virus showed less
growth capability than the wild-type virus. The NA of the H275Y mutant virus showed reduced substratebinding affinity and catalytic activity in vitro and delayed initial growth in MDCK and MDCK-SIAT1 cells.
These findings may in part explain its less efficient transmission. The fact that the oseltamivir-resistant
H1N1/2009 virus retained efficient transmission through direct contact underlines the necessity of
continuous monitoring of drug resistance and characterization of more NA inhibitor-resistant variants of
the pandemic H1N1 viruses.
We also sought to resolve the pending question about the naturally resistant seasonal H1N1 viruses by
investigating the changes of different seasonal H1N1 viruses in terms of NA genetics, NA proteins
attributes and virus fitness. We found that during the seasonal H1N1 virus evolution, two genetically
diverged lineages of H1N1 viruses were circulating at different times. The NA protein phenotypes of the
two lineages were naturally distinct in the levels of protein expression and enzyme affinity, and
accordingly, the H275Y NA mutation had differential effects on the NA proteins and virus fitness of the
two lineages. The new lineage NA proteins were inherently higher in protein expression and enzyme
affinity than the old lineage NA proteins and thus were able to tolerate the negative effects of the H275Y
mutation with a marginal loss of enzyme activity. As a result, the H275Y mutant H1N1 viruses of the new
lineage had virus fitness equivalent to the wild-type viruses and were able to continue circulating,
becoming the naturally resistant viruses. Further study revealed that 4 different amino acid substitutions
played different roles in maintaining high protein expression and enzyme affinity of the new lineage NA
proteins; the timeline of the sequential acquisition of the 4 substitutions was consistent with the timeline

of emergence of the naturally resistant H1N1 viruses. The identified NA tolerance to the H275Y mutation
in the naturally resistant seasonal H1N1 viruses also had implication on the virus fitness of the H275Y
mutant H1N1/2009 viruses, as well as on the continuing surveillance monitoring of circulating pandemic
H1N1 viruses.
Overall, both studies investigated in vitro and in vivo fitness of H275Y mutant H1N1 viruses relative to
their respective wild-type viruses, which were circulating in human beings at different times. These
studies correlated the viral fitness of the H275Y mutant viruses with the NA tolerance to the H275Y
mutation at protein level, and revealed that the NA tolerance to the H275Y mutation was the molecular
determinant of fitness of H275Y mutant H1N1 viruses. The studies have implications on surveillance
monitoring of the NA inhibitor resistance in circulating influenza viruses, which underlines the necessity
of continuous monitoring of drug resistance incidence, as well as potential genetic and phenotypic
changes of constantly evolving influenza viruses.
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ABSTRACT
Neuraminidase (NA) inhibitors including oral oseltamivir and inhaled zanamivir
are among the first line of defense against influenza virus infection. Development of
resistance to NA inhibitors is a huge drawback for limited options for the control of
influenza. During the first decade of NA inhibitor use, the detection rates of resistance to
both NA inhibitors had remained low in circulating influenza viruses. However, the
2008~2009 season was marked by a radical increase of prevalence of oseltamvir
resistance from <1% to >90% in worldwide surveillance in less than a year. The
resistance was solely linked to NA H275Y variants of seasonal H1N1 viruses, and they
are referred as the naturally resistant viruses. A big question remains open about what
fundamental molecular changes in the seasonal H1N1 viruses led to the surge of the
naturally resistant viruses. When this question remained pending, a novel swine-origin
H1N1 influenza virus emerged in Mexico at April 2009, soon spread worldwide
replacing the seasonal influenza viruses including the naturally resistant viruses, and
marked 2009 with the first influenza pandemic of the 21st century. With sustainably
increased worldwide use of NA inhibitors especially oral oseltamivir during the
pandemic, the oseltamivir-resistant variants carrying H275Y NA mutation were isolated
at low incidence from individuals receiving oseltamivir treatment and a few community
clusters. In view of the high prevalence of naturally resistant seasonal H1N1 viruses in
the immediate preceding season, there was an urgent need to characterize the
transmissibility and fitness of oseltamivir-resistant pandemic H1N1/2009 viruses,
although the resistance rates have remained low so far.
We first addressed the urgent question about pandemic viruses by investigating
the transmissibility of a closely matched pair of pandemic H1N1/2009 clinical isolates,
which only differed at the H275Y NA mutation in their genome, in the ferret model. We
found that the H275Y NA mutant H1N1/2009 virus was not transmitted efficiently in
ferrets via respiratory droplets, while it retained efficient transmission via direct contact.
The wild-type H1N1/2009 virus was efficiently transmitted via both routes. The
wild-type and the mutant viruses appeared to cause a similar disease course in ferrets
without apparent attenuation of clinical signs. In the growth competition in a ferret, the
H275Y mutant virus showed less growth capability than the wild-type virus. The NA of
the H275Y mutant virus showed reduced substrate-binding affinity and catalytic activity
in vitro and delayed initial growth in MDCK and MDCK-SIAT1 cells. These findings
may in part explain its less efficient transmission. The fact that the oseltamivir-resistant
H1N1/2009 virus retained efficient transmission through direct contact underlines the
necessity of continuous monitoring of drug resistance and characterization of more NA
inhibitor-resistant variants of the pandemic H1N1 viruses.
We also sought to resolve the pending question about the naturally resistant
seasonal H1N1 viruses by investigating the changes of different seasonal H1N1 viruses in
terms of NA genetics, NA proteins attributes and virus fitness. We found that during the
seasonal H1N1 virus evolution, two genetically diverged lineages of H1N1 viruses were
circulating at different times. The NA protein phenotypes of the two lineages were
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naturally distinct in the levels of protein expression and enzyme affinity, and accordingly,
the H275Y NA mutation had differential effects on the NA proteins and virus fitness of
the two lineages. The new lineage NA proteins were inherently higher in protein
expression and enzyme affinity than the old lineage NA proteins and thus were able to
tolerate the negative effects of the H275Y mutation with a marginal loss of enzyme
activity. As a result, the H275Y mutant H1N1 viruses of the new lineage had virus fitness
equivalent to the wild-type viruses and were able to continue circulating, becoming the
naturally resistant viruses. Further study revealed that 4 different amino acid substitutions
played different roles in maintaining high protein expression and enzyme affinity of the
new lineage NA proteins; the timeline of the sequential acquisition of the 4 substitutions
was consistent with the timeline of emergence of the naturally resistant H1N1 viruses.
The identified NA tolerance to the H275Y mutation in the naturally resistant seasonal
H1N1 viruses also had implication on the virus fitness of the H275Y mutant H1N1/2009
viruses, as well as on the continuing surveillance monitoring of circulating pandemic
H1N1 viruses.
Overall, both studies investigated in vitro and in vivo fitness of H275Y mutant
H1N1 viruses relative to their respective wild-type viruses, which were circulating in
human beings at different times. These studies correlated the viral fitness of the H275Y
mutant viruses with the NA tolerance to the H275Y mutation at protein level, and
revealed that the NA tolerance to the H275Y mutation was the molecular determinant of
fitness of H275Y mutant H1N1 viruses. The studies have implications on surveillance
monitoring of the NA inhibitor resistance in circulating influenza viruses, which
underlines the necessity of continuous monitoring of drug resistance incidence, as well as
potential genetic and phenotypic changes of constantly evolving influenza viruses.
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CHAPTER 1. GNERAL INTRODUCTION - NEURAMINIDASE INHIBITOR
RESISTANCE IN INFLUENZA A VIRUSES: MOLECULAR MECHANISM
AND VIRUS FITNESS
Influenza Viruses and Influenza Disease
Influenza viruses are among the most important human-inflicting pathogens.
Influenza viruses are enveloped viruses with single-stranded negative-sense segmented
RNA genome, belonging to the members of the orthomyxoviridae family. Influenza
viruses can be classified into A, B, C types. Human influenza viruses are mainly A and B
type. Influenza B is separated into Yamagata and Victoria lineages. In influenza A
viruses, two virus surface glycoprotein hemagglutinin (HA) and neuraminidase (NA)
determine and differentiate their antigenic subtypes into 16 HA subtypes and 9 NA
subtypes (1). All these influenza A subtypes can be found in their natural reservoir
aquatic birds (2). Only three HA subtypes (H1, H2, H3) and two NA (N1, N2) subtypes
have been found to cause efficient infection in human populations, including human
H1N1, H2N2 and H3N2 subtype viruses. In addition, occasional human cases of the
infection with avian influenza A viruses of H5, H7 and H9 subtypes have been
reported (3-5). In circulating human influenza viruses, HA and NA surface proteins
constantly evolve to escape the accumulated herd immunity pressure against the two
proteins by acquiring mutations at their antigenic sites known as antigenic drift. In
addition, the reassortment ability between two different influenza virus strains can
generate a new strain of virus which possesses distinct surface proteins from their
parental viruses, known as antigenic shift.
Influenza viruses cause an acute contagious disease in the respiratory tracts influenza. Every year, human seasonal influenza viruses which are mainly co-circulating
influenza A H1N1 and H3N2 subtypes and influenza B type, cause annual influenza
epidemics. The typical clinical symptoms of human influenza virus infection include
coughing, sneezing, sore throat and fever. Severe disease including pneumonia and other
systematic symptoms are normally limited to the susceptible populations such as
immunocompromised patients, young children and elderly people. Although the seasonal
influenza outbreaks normally tend to be mild, they still cause thousands of deaths and
millions of hospitalizations annually. Periodically, new strains of influenza viruses can
emerge from different species and rapidly spread into human beings, causing world-wide
outbreaks of infection - influenza pandemics. Historically, there are serious pandemics in
the 20th century with numerous death caused by different influenza viruses H1N1, H2N2,
and H3N2, respectively (2). Most recent example is the 2009 H1N1 influenza virus
pandemic, the first pandemic in the 21st century caused by a novel swine-origin influenza
virus of H1N1 subtype (6;7). The most confirmed human cases of H1N1/2009 influenza
have been uncomplicated and mild, but the number of cases and affected countries was
unprecedented. In addition, human infection of avian influenza viruses had variable
clinical outcomes, with symptoms involving typical influenza symptoms and other,
pneumonia, rhihnorrhea, diarrhea, hypoxemia and leucopenia systematic symptoms (8).
The human cases of avian H5N1 influenza virus infection, which sporadically occurred at
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South East Asia and Middle East Africa (9), are especially associated with extremely
high mortality and morbidity. Although transmission of H5N1 influenza viruses from
avian species to humans is currently inefficient, the novel antigenicity of the viruses for
human populations and the highly fatal outcome of the infection raised huge concern
about their potential to become the next pandemic virus and the severity of the potential
pandemic.
Structure and Replication of Influenza A Virus
Virion structure of influenza A virus. Virions of Influenza A virus are
lipid-enveloped particles, typically displaying roughly spherical shape or long filament
shape (1;10). The virions have three transmembrane proteins including two surface
glycoproteins HA and NA and one membrane-embedded M2 protein. HA protein is the
most abundant envelope protein (80%). They are rod-shaped trimer molecules with C
terminus forming a membrane anchor inserted into viral membrane and N terminus
forming a globular head projected away from viral surface like a spike. NA protein is the
second major envelope protein (17%) and is cluster together as patches on the viral
membrane. NA protein is mushroom-shaped tetramer molecule with a short N-terminal
cytoplasmic tail and transmembrane region as anchor for the stalk and head. M2 protein
has very minor abundance among envelope proteins and it is also a tetramer molecule
which forms ion channels spanning the envelope. On the interior side of the virion lipid
envelope, a matrix formed by M1 protein holds 8 viral ribonucleoprotein (vRNP)
complexes in each virion. Each vRNP complex is made up of one RNA gene segment
coated by nucleoproteins (NP) and associated with a polymerase complex of PB1, PB2
and PA proteins. The virions also contain Nanostructure Protein 2 (NS2), sometimes also
called nuclear export protein (NEP). The 8 genome segments of influenza A viruses
encode for 10 viral proteins. Six segments encode HA, NA, NP, PB1, PB2, PA proteins
respectively, and the mRNAs of 2 segments, M and NS segments can be alternatively
spliced into M1/M2 and NS1/NS2 genes respectively. Among the 10 viral proteins,
except for NS1 protein, other 9 proteins are incorporated into the virus particles during
virus replication. In some influenza A viruses, the +1 reading frame of PB1 gene can
encoded an additional protein PB1-F2 of up to 90 amino acid residues (11). PB1-F2
proteins are truncated in some influenza A viruses, due to the frequent appearance of stop
codon in the alternative reading frame of PB1 gene. Each protein function differently and
concertedly during replication cycle of influenza A viruses.
Life cycle of influenza A virus. Concisely, the replication cycle of influenza A
virus in cells can be divided into several phases (10): virus entry into host cells, import of
vRNPs into the nucleus, transcription and replication of viral genome, export of nascent
vRNPs from the nucleus, assembly and budding of progeny virions, and finally release of
the progeny viruses from infected host cell surface. Each phase is involved with multiple
molecular events mediated by different host and viral factors and a lot of precise details
in these events are still under investigation.
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Influenza A virus replication start from the entry of virus particles into host cells.
This phase is involved several steps including virus attachment, endocytosis of virus
particle, fusion of viral envelope with endosomal membrane and uncoating of virus
particle within endosome (1;10). The surface glycoprotein HA plays several different
critical roles during these steps. The HA protein is synthesized as a single polypeptide
precursor HA0. For most influenza viruses, the HA0 must be cleaved by host proteases
into HA1 and HA2 subunits which are linked by disulphide bonds. HA1 subunit contains
receptor binding domain, and HA2 subunit contains transmembrane domain and a fusion
peptide. Influenza A virus entry starts from virus attachment to host cell surface by the
interaction of the HA receptor binding domain with the sialic acid containing-receptors at
host cell surface. Upon binding to the cell surface, the virus is internalized by
receptor-mediated endocytosis. Being inside an endosome, the virus enters into the host
cell. When the endosomal pH is decreased to ~5 by action of an H+ pump on the
endosomal membrane, the low pH induce an irreversible confirmation change of the
whole cleaved HA molecule, which expose and realign the fusion peptide in the HA2
subunit. The realigned fusion peptide bring the viral and endosomal membranes into
contact with each other and insert itself into the endosomal membrane. The action of
more than two fusion peptides form the fusion pores in the membrane of the virion,
enabling release of the content of the virion into cell cytoplasm. The acidic environment
in the endosome also open M2 ion channels in the viral membrane, allowing the influx of
H+ ions from endosome into the virion. The acidification of the virion disrupts vRNPs
binding to M1 proteins, leading to the release the free vRNPs into cyctoplasma, which
complete the uncoating process.
After the vRNPs are released into the cytoplasm, they are to be imported into the
nucleus, where they serve as templates for transcription and replication of virus
genome (1;10). All proteins in vRNP complex including NP, PB1, PB2 and PA possess
nuclear localization signals (NLSs), which interact with cellular nuclear import
machinery and mediate the vRNP import into nucleus. Once in the nucleus, in order for
synthesis of the viral proteins, each negative-sensed RNA segment is transcribed into
messenger RNA (mRNA), which is capped and polyadenylated positive-sensed RNA for
protein translation. For replication of the viral genome, each negative-sensed RNA
segment is firstly transcribed into an exact positive-sensed complementary RNA (cRNA)
copy, then in turn the cRNA serve as template for synthesis of more copies of
negative-sensed viral RNA (vRNA). All these transcription and replication of viral RNA
segments are catalyzed by the same viral polymerase complex, an RNA-dependent RNA
polymerase complex made up with three subunits PB1, PB2 and PA. The viral mRNAs
are transported to the cytoplasm and serve as templates for translation of viral proteins.
NS1 protein is believed to block the transportation of host cell mRNAs thus facilitating
the viral mRNA process. Newly synthesized M1, NP and NS2 proteins are imported back
into the nucleus for assembly and transportation of new vRNPs. Following virus
replication, newly formed vRNPs are assembled in the nucleus and are to be exported
into the cytoplasm. It is believed that M1 protein and NS2 protein are involved in this
process by masking the NLS in the proteins of vRNPs and also interacting with nuclear
export machinery respectively.
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After the vRNPs have been exported into cytoplasm, they are to be packed with
other viral proteins into virus particles to leave the cells (1;10). This process occurs at the
apical plasma membrane of polarized cells and involves with multiple events including
assembly of different viral components, package of all 8 segments, membrane budding
and release of nascent virons. The three transmembrane proteins are assembled into
trimers (HA) or tetramers (NA and M2) in cell endoplasmic reticulum, and then they are
directed to assembly sites and are further incorporated into cell membrane by the signals
residing in the transmembrane domains of HA and NA proteins. Other viral components
including viral segments also reach the assembly sites and are poised for virion budding.
Virus budding is seen as the extrusion of cell membrane along with all the virus
components in its inner core and eventual formation of virus particles after the fission
from the cell membrane. M1 is believed as the driving force behind this process. After
completion of virus budding, the virus particles are attached to the infected cell surface
due to HA binding to the sialic acid-containing receptors, so the progeny virions cannot
leave cell membrane without active release by the action of NA. The enzyme activity of
NA proteins cleaves the sialic acid residues from glycoproteins and glycolipids on the
cell membrane, thereby releasing the progeny virions into extracellular environment to
infect new host cells.
Influenza A Virus Molecular Determinants on Pathogenesis and Transmission
Each viral protein of influenza virus plays different and indispensable role in virus
life cycle and they are tightly regulated and coordinated with host factors to cause an
effective virus infection in a host. Primarily all the viral proteins contribute to successful
infection of influenza A virus in hosts, although the precise action mechanism of each
viral protein on the virus pathogenesis and transmission in hosts is still to be further
explored. Studies of different subtype influenza A viruses of different properties have
identified several dominant viral molecular determinants on virus pathogenesis and
transmission (2;12;13).
Two major functions of HA protein, receptor-binding and fusion activity, both
contribute to virus transmission and pathogenesis (2;12;13). Firstly, HA proteins have
specificity for recognition of host cell receptors, making HA a determinant for influenza
virus host range. Now, it is generally believed that HA proteins of human influenza virus
isolates preferentially binds to Į2,6-linked sialic acids, while HA proteins of avain virus
isolates preferentially binds to Į2,3-linked sialic acids (14). Mainly Į2,6-linked sialic
acids are found in human upper respiratory tract, the primary site of influenza infection,
which impose a restriction for efficient transmission of avain influenza virus into human
beings. Accordingly, virus possession of HA recognizing human-type receptors is also
seen as a pre-requisite for sustained human-to-human transmission of the virus. Secondly,
HA precursor cleavage is essential for viral infectivity and cleavability of HA precursor
is a restriction factor for effective virus replication. The HA proteins of most of influenza
A viruses only posses a single Arg residue at the cleavage site, which must be cleaved by
host cell proteases in respiratory or intestinal organs, thus the virus replication is
restricted locally within these organs. In contrast, the HA proteins of highly pathogenic
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H5 or H7 viruses possess multi-basic amino acids at the cleavage site (15), which allows
their proteolytic cleavage by universal unbiquitous proteases during HA peptide
post-translational modification and leads to severe systemic infection. Therefore, the
multi-basic HA cleavage motif is seen as a virulence factor for influenza virus.
The replication capability of polymerase complex of influenza A virus contributes
to virus pathogenicity by directly controlling virus growth in hosts. Several mutations
such as E627K and D701N in PB2 subunit are associated with the polymerase replication
ability, thus virus pathogenicity and transmission (2;12;13). PB2 E627K mutation in the
avian H5N1 influenza viruses can enhance the polymerase replication ability in 33°C, but
not at higher temperature 37ºC and 41°C (16). 33°C is the approximate temperature of
mammalian upper respiratory tract where human influenza viruses replicate, whereas
41°C is the approximate temperature of avian intestinal tract where avian influenza
viruses replicate. Therefore, avian H5N1 influenza viruses with PB2 E627K mutation had
increased pathogenicity in mammalians (17). In contrast, PB2 K627E mutation in the
human influenza A viruses reduces virus transmission in mammalian animal models due
to reduced replication in their upper respiratory tracts (18).
PB-1 F2 is a small protein of up to 90 amino acid residues encoded by an
alternative reading frame of PB1 gene and it can be truncated at different lengths by
different location of stop codon in the alternative reading frame. PB1-F2 preferentially
localizes to mitochondria membrane in the infected cells and has a pro-apoptotic
function (11). PB1-F2 also can enhance the virus polymerase activity in vitro (19). An
S66N mutation in PB1-F2 mutation was found to be responsible for the high virulence of
both 1918 pandemic and avian H5N1 influenza viruses (20). Therefore, PB1-F2 is also
known as virulence factor of influenza viruses.
Pathogencity of influenza A viruses also depends on their ability to evade host
immune response, especially the first line innate response as influenza viruses only cause
acute infection. NS1 protein is found as an interferon antagonist to suppress host innate
response to viruses (21). NS1 prevents activation of certain transcription factors thus also
the following stimulation of interferon production. The NS1 proteins of highly
pathogenic H5N1 viruses are associated with induction of high levels of
pro-inflammatory cytokines in hosts, which was linked to the severe inflammation and
high morbidity and mortality caused by the viruses (2;22). Several mutations such as
D92E and P42S in NS1 protein of the H5N1 viruses have been linked to virus
virulence (23;24).
The enzyme activity of NA function mainly functions to actively release progeny
virus particles from infected cell surface. NA is also believed to function to cleanse the
respiratory tract environment such as mucus and cell surface for virus entry by removing
the sialic acid from host glycoproteins or glycolipids. In addition, NA also can prevent
virus particle aggregation and allow virus spread (25). Efficient influenza A virus
replication requires an optimal functional balance between HA sialic acid-binding
activity and NA receptor-destroying activity. The balance can be disturbed by
reassortment between different virus strains, interspecies transmission etc events and the
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changes of function NA and their impacts on virus infectivity during these events have
been described (26;27). Especially during antiviral treatment, influenza virus can adapt to
NA inhibitor drugs by generation of resistant viruses of NA mutations. How these NA
mutations cause resistance to NA inhibitors and how they affect NA function and fitness
of the mutant viruses including virus pathogenesis and transmissibility is the focus of this
review as discussed below.
Interventions of Influenza Infection
Vaccination and Antiviral Medication
Vaccination is one of the effective interventions for influenza infection, primarily
for preventing infection and reducing the morbidity and mortality associated with the
influenza infection. Seasonal influenza vaccines, either the trivalent inactivated virus
vaccine or the live attenuated virus vaccine include contemporary H1N1 and H3N2
influenza A virus and influenza B as the three antigen components. The three antigen
components have to be evaluated annually based on the contemporary prevalence of the
circulating viruses, and are subject to reformulation when the antigenicity of prevalent
circulating viruses changes. Thus, the efficacy of vaccination is largely determined by the
matches between circulating viruses and selected vaccine strains and can be significantly
reduced by mismatches. Additionally, the efficacy of vaccination is also limited by the
adequacy of host immune response against the vaccine antigens, the complication of the
pre-existing immunity mounted in individuals especially adults. More importantly, in the
scenario of a pandemic which are caused by emergent influenza viruses with new
antigentic features, there is considerable delay time, normally at least 6 months, before a
sufficient amount of the new antigenically-matching vaccines can be produced.
Thus, antiviral medication provides another option for the control and
management of acute influenza infection. The goal of antiviral treatment is to decrease
the disease associated symptoms, complications, mortality etc. Specific anti-influenza
drugs have also been used for both prophylactic and therapeutic treatments of influenza
infection during seasonal epidemics. Antiviral medication is particularly important at the
beginning of a fast-spreading pandemic, and it is even likely to become the only first-line
control strategy before the antigenically-matching vaccine is available. The beneficial
effects by the antiviral medication on patients including reducing virus shedding duration,
illness symptoms and functional disability caused by the illness, although the magnitude
of the efficacy varies, depending on the drugs used, the populations treated, the viruses
infected and the timing of the treatment initiation etc.
Influenza Virus-specific Antiviral Drugs
At present, there are two classes of FDA-approved antiviral drugs specific for
influenza viruses, M2 blockers and NA inhibitors. M2 blockers including amantadine and
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rimantadine were the earliest class of specific anti-influenza compounds. Amantadine
was approved by FDA as early as at 1963 and rimantadine at 1993. This class of drugs
targets the M2 ion channel located in the viral membrane. Binding of the drugs in the
channels blocks virus uncoating thus prevent its following replication inside the cell. M2
blockers are only effective against influenza A virus. They are effective for prophylaxis
and therapeutic treatments of influenza infection and exert clinic benefit including
decreased duration of virus shedding and disease symptoms in patients (28). The
resistance to M2 blockers are developed during treatment and conferred by amino acid
residues changes in the M2 ion channel, most notably at S31N. The prevalence of the M2
blocker resistance is a serious problem for this class of drugs: to date, it has been reported
of >90% resistance rate in seasonal H3N2 viruses, overall 15% rate in seasonal H1N1
viruses, 100% rate in all characterized 2009 pandemic H1N1 viruses, and varied rates
including as high as 90% in certain clades of avian H5N1 viruses (29) (30;31) . The
high-level circulation and rapid spread of the resistant influenza viruses in the community
have compromised the usefulness of the M2 blockers.
Another class of specific influenza virus-specific antivirals is the NA inhibitors,
including oral oseltamivir and inhaled zanamimir which were approved by US FDA at
1999 for treatment of influenza infection (32). The third investigational NA inhibitor,
peramivir developed as intravenous formulation, has been licensed only in Japan, but is
in ongoing clinic trails in US now (28). Based on its promising efficacy, it was warranted
by US FDA with an emergency use authorization for treatment of 2009 pandemic
influenza virus infection in certain patients (33). NA inhibitors now are the first line of
specific anti-influenza drugs due to the high prevalence of resistance to the M2 blockers
in human influenza A viruses and the lack of activity against influenza B viruses of the
M2 blockers.
Mechanism of Action of NA Inhibitors
NA inhibitors target the NA enzyme, one of the membrane glycoproteins
presented at the surface of the influenza virus particle. Influenza virus NA functions to
cleaves the Į-2,3- or Į -2,6-ketosidic linkage between a terminal sialic acid residue and
an adjoining sugar residue (28;34). In the influenza virus replication cycle, by removing
the sialic acids residues from the membrane surfaces of infected cells, NA destroys the
association between infected host cells with HA proteins, thus facilitating the release the
nascent viruses and allowing the progeny viruses to infect new host cells (28;34).
All type/subtypes of influenza viruses have abundant NA proteins in their
membranes, and the main structure and critical amino acid residue at the enzyme active
site are highly conserved among all NA stubypes of influenza viruses, although the NA
protein constantly evolves under immunity pressure and continuously changes the amino
acid residue composition. 19 conserved residues were identified at the NA active site:
including 8 catalytic residues (R118, D151, R152, R224, E276, R292, R371, and Y406;
N2 numbering) which directly interact with the sialic acid substrate during the enzyme
reaction, and 11 framework residues (E119, R156, W178, S179, D/N198, I222, E227,
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H274, E277, N294, and E425) which support structure and function of the active
site (35). NA inhibitors were all developed through rational drug designs based on the
knowledge of the crystallographic structure of the NA complex with sialic acid (36;37).
All three NA inhibitors, oseltamivir, zanamivir and peramivir are analogues of
sialic acid, the natural substrate of the NA enzyme (36). NA inhibitors competitively bind
to the NA active site, and thus block the binding of sialic acid, its natural substrate.
Owning to the essential role of NA for release of progeny virions from the infected host
cells, the inhibition of NA prevents virus spread and future replication in adjacent cells in
the host. The mode of action of the NA inhibitor was proved by electron microscopy
imaging (25). In the electron microscopy images, in the absence of inhibitor, separate
rounded virions were observed on the surface of the cells; in the presence of oseltamivir
carboxylate, clumped flattened virons were observed to attach to the cell surface,
suggesting the failure to detach from the cell surface (25). As the neuraminidase active
site is highly conserved in all types of influenza viruses, the NA inhibitors are effective
against all human, avian and animal influenza viruses (25). The antiviral activity of the
NA inhibitors have been demonstrated and proved in NA enzyme inhibition assays in
vitro, infectivity reduction assays in cell culture, experimental animal models and human
treatment experience (25;30).
NA Inhibitor Resistance in Influenza A Viruses - Mechanism, Prevalence and
Fitness
The resistance to NA inhibitor can greatly reduce the therapeutic efficacy and
disable the limited infection control options for influenza, so the susceptibility of the
circulating influenza viruses to NA inhibitors have been closely monitored in clinical
observation studies and surveillance studies.
Assessment of susceptibility of influenza viruses to NA inhibitors is primarily
performed in functional NA inhibition assay in vitro and the NA genes of resistant
viruses were further sequenced to understand the mechanism of resistance (38). The
susceptibility of the virus to the drug can be firstly defined by the 50% percentage of
inhibition concentration values (IC50) in NA inhibition assays. IC50 values vary by the
type NA inhibition assay, influenza type and NA inhibitors tested, so the folds of change
of IC50 values have been set as the criteria defining NA inhibitor resistance which is
IC50 >10-fold means of the reference type/subtype sensitive influenza viruses to the
drug (38). Thus, a significant increase of the IC50 value of a virus to a drug compared to
the sensitive viruses can be defined as resistance or reduced susceptibility, although there
is no clear-cut standard to differentiate both terms. Before the NA inhibitors were
approved for clinical practice, over 1000 influenza virus isolates were examined for their
susceptibility to NA inhibitors and they were found to be naturally sensitive (25).
When influenza viruses resistant to NA inhibitors are identified, the resistance
phenotype can be mapped to NA mutations by genotyping methods. The known
resistance markers have been mapped to either the catalytic residues or framework
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residues of NA active site. Apart from characterization of resistant virus genotype and
phenotype, the impacts of resistance-associated mutations on the function of NA protein
can be evaluated by enzyme kinetics, such as Km, Ki and Vmax etc parameters. Km is
the dissociation constant for enzyme binding to the substrate, which is intrinsic to the
enzyme and independent of the amount of protein presented in the reaction; Likewise, Ki
is the dissociation constant for enzyme binding to the enzyme inhibitor; Vmax reflects
catalytic capability of the enzyme active site and is dependent on both the enzyme
turnover rate (Kcat) and the amount of enzyme presented in the reaction.
After resistance genotype and phenotype of influenza viruses are characterized,
the fitness of resistant viruses is of particular interest for further investigation. Viral
fitness is defined as the degree of virus adaptation to a given environment or its relative
ability to produce infectious progeny in a host (39). Originally, a growth competition
experiment between different viruses is adopted to define the fitness degree of a virus
relative to another virus (39) (40). However, due to the difficulty to quantitatively
differentiate different genotypes in mixed populations, growth competitions cannot be
always easily realized. As an alternative, now a comparative experiment using different
viruses under the same experimental settings generally can be used to describe the fitness
level of a virus relative to other viruses. The virus fitness can be evaluated in vitro or in
vivo, such as virus growth kinetics and capability in different cell cultures, virus plaque
morphology in cells and virus growth, pathogenicity and transmissibility in animal
models etc infectivity parameters.
In the follow sections, the mechanism and prevalence of the resistance to NA
inhibitors in influenza A viruses is discussed, which includes human seasonal influenza A
viruses, 2009 pandemic H1N1 viruses and emerging highly pathogenic H5N1 virus
infection in human beings. The virus fitness of NA inhibitor-resistant viruses of different
subtypes in comparison to their respective wild-type viruses in experimental models is
also discussed, especially with a focus on the virus transmissibility, one of most clinical
relevant properties of influenza A viruses.
NA Inhibitor Resistance in Human Seasonal Influenza A Viruses
Drug-selected resistance in human seasonal H1N1 and H3N2 influenza A
viruses. After the NA inhibitors were approved for clinical use in 1999, the resistance to
NA inhibitors emerged in clinical isolates during the NA inhibitor treatment in patients
infected with seasonal H1N1 or H3N2 influenza viruses (41). The isolation of the
resistant variants was associated with NA inhibitor treatment; as a result, they are referred
as drug-selected resistance. In the clinical-derived resistant variants, NA inhibitor
resistance associated mutations are found to be subtype-specific and drug-specific
(32;42), either catalytic residues or the framework residues at the active site. It has been
systematically summarized about the resistance-associated mutations found in the human
seasonal influenza viruses of different type/subtype, and the susceptibility change to the
three NA inhibitors caused by these mutations (32;42). With a focus on clinical isolates
only, concisely, the catalytic residue R292K and framework residue E119V mutations
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predominate in resistant H3N2 viruses; I222V mutation was reported occasionally in
H3N2 viruses and N294S mutation was reported in one case of H3N2 virus infection,
whereas the framework H274Y/H275Y (N2/N1 numbering; the actual numbering in the
respective subtype were used afterwards) mutation is the most frequent resistance marker
in H1N1 viruses. At the molecular function level, R292 is part of catalytic residues of
enzyme active site responsible for binding to sialic acid and changing its conformational
shape during reaction (43;44). The R292K mutation blocked the binding the NA
inhibitors or sialic acid, consequently causing crossing-resistance to all three NA
inhibitors. E119V mutations at the framework may permit a water molecule binding into
the space of the residue Valine (V), which interfere with binding of oseltamivir but not
zanamivir or sialic acid to the active site (45), therefore, E119V only results in resistance
to oseltamivir, but not to the other two NA inhibitors. The H275Y mutation at the
framework does not directly affect the enzyme catalytic sites, but it prevents the
reorientation of E277 residue, which is required to accommodate oseltamivir to bind into
the active site (43-45). Thus, the H275Y mutation only induces resistance to oseltamivir,
not to other two NA inhibitors. It has been proposed that the R292K and N294S mutation
may also prevent the reorientation of the E277 residue during the drug molecule
binding (44;45).
Serial passages of influenza A viruses in the presence of the NA inhibitors in cells
or generation of reverse genetic viruses with the mutation at conservative amino acid
residues in NA active site have created more NA inhibitors-resistant variants in vitro,
with different levels of resistance to NA inhibitors (32;42). The resistance associated NA
mutations identified in vitro is a growing list, which includes but is not limited to D151E,
R152K, R371K, R118K, R224K, E227D, E276D, E119G/D/E etc mutations (N2
numbering) (32;42). These mutations have not been found in the clinical isolates yet,
perhaps due to their extremely reduced virus replication and infectivity, but they are of
interest to understand the catalytic mechanism of NA active site and of implication for
surveillance monitoring of NA inhibitor susceptibility.
The detection rates of resistance from patients receiving NA inhibitor treatment in
different clinical trials and clinical observation studies varied, depending on the treated
subject and influenza virus type/subtype. For seasonal influenza A viruses, the incidence
generally remained at low level till 2007. In early clinical trials of oseltamivir use for
treatment of seasonal influenza, the emergence rate of resistance was about <1% in adults
and 4~8% in children during the treatment, where the resistance was associated with
H275Y mutation in H1N1 viruses, E119V and R292K mutation in H3N2 viruses (41;46).
In later clinical observations, increased frequency of resistant variants detection (16% and
27%) in drug-treated children was observed, and the resistance was also solely linked to
the H275Y mutation in H1N1 viruses (41;47).
The surveillance studies of NA inhibitors susceptibility of community isolates,
which had no identified history of antiviral use in association with collection of the
original clinical specimens, are informative to provide the prevalence of resistance in
circulating viruses. Two early surveillance studies (46;48) conducted during the first
three years of NA inhibitor use (2000~2003) tested thousands of influenza virus isolates
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collected worldwide, and found no isolate or only 8 isolates resistant to oseltamivir
respectively (0% or 0.33% resistance rate respectively), which suggesting extremely low
prevalence of resistant viruses by then. More surveillance studies (32;49;50) conducted
between 2003~2007 by different groups tested more influenza virus samples either
collected globally or regionally from different countries including the ones of greatest
oseltamivir use, constantly showed very low resistance rates (0.5%~1.7%) in
characterized samples, suggesting that the very low prevalence of resistance in circulating
viruses and no potentially transmissible resistance. However, the situation changed
dramatically during the 2007-2009 season, when seasonal H1N1 viruses with common
H275Y NA mutation were detected with high prevalence world widely under the context
of absence of oseltamivir use (45). In differentiation with the drug-selected resistance
above, this special phenomenon in the history of NA inhibitor resistance monitoring is
referred as naturally occurring resistance and is further discussed in the section below.
The virus fitness of NA inhibitor-resistant seasonal influenza viruses including
infectivity and transmissibility compared with respective to wild-type viruses have been
studied in experimental animal models (51-53). As regards to H1N1 viruses, in an earlier
study, the H275Y mutant viruses exhibited severely compromised replication and
virulence both in vitro and in ferrets compared to the wild-type viruses (54;55). The
transmissibility of H275Y mutant viruses were firstly investigated in a ferret direct
contact model, and the direct-contact transmission of a H275Y mutant of A/New
Caledonia/20/99-like (H1N1) virus required a higher dose of inoculums than transmission
of the wild-type viruses, and it occurred more slowly (53). Regarding to H3N2 viruses,
an R292K mutant of A/Sydney/5/97-like H3N2 virus exhibited severely compromised
infectivity and replication ability in ferret in comparison with the wild-type virus (55),
and was not transmitted by direct contact among ferrets under the same conditions where
the wild-type virus was transmitted (52). In a subsequent study, under similar conditions,
an E119V NA mutant of A/Wuhan/359/95-like (H3N2) virus by ferret was transmitted by
direct contact among ferrets but required a higher dose of inoculums than the wild-type
virus, and the transmission occurred more slowly than the wild-type virus (53). In a
different animal model, recombinant H3N2 influenza viruses carrying the E119V NA
mutation or the double mutations E119V and I222V were transmitted efficiently among
guinea pigs by direct contact but not by aerosol in comparison with the wild-type
virus (51).
These earlier studies differed in the virus subtypes studied (H1N1, H3N2), the NA
mutations involved (H275Y, R292K, E119V or I222V), the animal model used (ferret or
guinea pig), and the transmission routes studied (direct contact and respiratory droplets),
but they commonly and consistently showed the virus fitness including infectivity and
transmissibility of the NA inhibitor-resistant viruses carrying different NA mutations was
lower sometimes even severely lower than the respective sensitive wild-type viruses,
therefore, the NA inhibitor-resistant viruses were thought unlikely to be of clinical
consequence. However, the later studies of virus fitness of the naturally resistant H1N1
viruses showed very contrasting results, which were discussed in below section.
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Naturally-occurring resistance in human seasonal H1N1 influenza A viruses.
An exceptional phenomenon in the NA inhibitor resistance detection called
naturally-occurring oseltamivir-resistance was observed in the seasonal H1N1 influenza
viruses during two influenza seasons between 2008~ 2009 (45). During these seasons, the
H1N1 influenza viruses with the common oseltamivir-resistance NA mutation H274Y
(274 in N2 numbering, 275 in N1 numbering) were detected with high prevalence world
wide under the context of absence of oseltamivir use (31;45;56). This particular
phenomenon was a striking change compared with the situation during the years prior to
2007, when the resistance incidence were usually connected with drug use and the
detection rates were rather low. In differentiation with the drug-selected resistance, this
special phenomenon is referred as naturally-occurring oseltamivir-resistance caused by
the naturally resistant H1N1 viruses carrying the H275Y NA mutation in circulation.
The naturally-occurring oseltamivir-resistance was firstly observed in Europe
during the 2007-2008 season (57). In January 2008, Norway was the first to report high
prevalence (68%) of resistant H1N1 viruses carrying the H275Y mutation in circulation
(58). In early 2008, an average prevalence of resistant H1N1 viruses reached to 56%
across the Europe (57). The resistant H1N1 viruses continue to spread to the southern
hemisphere in following influenza season, such as Oceania, South Africa and South East
Asia etc regions (59). By mid 2008, the southern hemisphere influenza season marked by
a dramatic increase of the resistance rates from <1% to >90% in less than a year (59). In
the following 2008~2009 influenza season, almost 100% of tested circulating H1N1
viruses were resistant H275Y mutants in North America and other regions of the world
(60). Clearly, the naturally resistant H1N1 variants were becoming the dominant
circulating strains until the swine-origin pandemic 2009 H1N1 virus emerged.
The rapid global surge of naturally resistant H1N1 viruses suggests that these
H275Y mutant viruses owned higher virus fitness including transmissibility than their
precedent wild-type viruses, although the previous epidemiologic and experimental data
suggested otherwise. In view of this controversy, one study compared the effects of the
H275Y mutation on the replication and virulence of old and recent influenza H1N1
viruses (61). The results showed that the H275Y mutation caused impaired virus growth
in cells only in the old A/WSN/33 virus but not in the recent A/Brisbane/59/07-like virus;
the virulence of the recent A/Brisbane/59/07-like H275Y variant virus was not reduced in
ferrets compared with the wild-type virus, consistent with its global dissemination.
It has remained a puzzling question for a long time about the underlying
mechanism of the optimal fitness of these naturally resistant H275Y mutant viruses,
because the previous epidemiologic and experimental data suggested otherwise about
fitness of the H275Y mutant H1N1 viruses. Surveillance studies provided informative
clues for this question by examining the genetic changes in the H275Y mutant H1N1
viruses. The phylogenetic analyses by different groups using various circulating H1N1
viruses collected from respective regions showed two common features of these viruses
(62-66). First, the NA and HA genes of seasonal H1N1 viruses exhibited same cluster
patterns, which were classified as Clade 1, Clade 2A, 2B, 2C, represented by H1N1
vaccine strains New Caledonia/20/1999 virus, Solomon Island/23/2006 virus,
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Brisbane/59/2007 virus respectively (though no vaccine strain representing the
Clade 2C); second, the vast majority of the naturally resistant viruses belonged to the
Clade 2B in the phylogeny. Some studied further looked the genetic makeup of entire
genome of the sensitive and resistant viruses and found that certain NA and HA amino
acid substitutions and some intra-subtype reassortment events were associated with the
naturally resistant viruses in phylogeny (65;66). These findings of genetic features in the
naturally resistant viruses, especially their NA genes clustering together in the Clade 2B
are enlightening to further understand their underlying molecular mechanisms.
Two pioneering studies discovered different molecular phenotypes of the
naturally resistant H1N1 viruses from different angles (67;68), and significantly
advanced our understanding of the molecular mechanism of the naturally resistant H1N1
viruses. The visionary work by M.A Rameix-Welti et al (68) , for the first time, revealed
the distinct levels of NA enzyme affinity and distinct cluster patterns of the HA and NA
genes among the old and newer isolates of seasonal H1N1 viruses. This study also
showed that all the tested naturally resistant H275Y mutant viruses belonged to the high
NA affinity group which genetically clustered together in the same group. This particular
cluster was recognized as Clade 2B later and was consistently showed as a common
feature for the naturally resistant H1N1 viruses characterized in different studies (62-66).
Further studies have associated the high enzyme affinity in some viruses to certain NA
amino acid substitutions (63;69) and one study confirmed the role of D344N substitution
in increasing enzyme affinity (70). Another pioneering work by Bloom J. D et al (67), for
the first time discovered that surface accumulation of a NA protein was reduced by the
H275Y mutation and this defect could be counteracted by two permissive mutations
Q222R and V234M which appeared prior to the H275Y mutation in the H1N1 virus
evolution. This study is of significance to be the first to move the understanding of the
effects of the H275Y mutation to protein expression level and firstly proposed the
concept of “permissive” mutations for the H275Y mutation from the perspective of gene
evolution. Following this findings, a recent study confirmed that the substitutions of the
identified “permissive” residues into the “unpermissive” residues in the NA gene of a
recent Clade2B virus compromised the corresponding H275Y mutant virus in vitro and in
vivo (71).
It remains an uncertain question where these naturally resistant H1N1 influenza
viruses originated in the first place. As the H275Y NA mutation was not detected in
influenza viruses in nature before the oseltamivir was approved for use at 1999, most
likely, the progenitor H275Y mutant virus of the naturally resistant viruses still firstly
emerged from the oseltamivir-treated patient under drug pressure, and the H275Y
mutation was fixed into the ensuing virus population as a results of the identified
permissive mutations and/or other unidentified mechanisms. The viruses carrying the
H275Y mutation were further transmitted and spread, eventually becoming the naturally
resistant H1N1 viruses. Another different and intriguing hypothesis about the origination
of resistance is that the NA mutations at the enzyme active site could be a byproduct of
HA protein avidity change resulted from immune escape of neutralizing antibodies (27).
This study showed that HA immune escape of neutralizing antibodies resulted in NA
antigenic variation and acquisition of NA mutations including H274N, V118I and
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K253R, one of which altered the virus susceptibility to NA inhibitors. Although it
remained uncertain what prompts the selection of those NA mutations, it provides an
alternative view of the origination of the drug resistance.
NA Inhibitor Resistance in 2009 Pandemic H1N1 Influenza A Viruses
A novel swine-origin H1N1 influenza virus emerged in Mexico in April 2009 and
rapidly spread worldwide, causing the first influenza pandemic of the 21st century. Most
confirmed human cases of 2009 pandemic H1N1 virus (pH1N1) infection have been
uncomplicated and mild, but the increasing number of cases and affected countries, and
the sustained human-to-human transmission of the viruses, warranted optimal prevention
and treatment measures. All tested the pH1N1 viruses carried resistant makers at M2
gene to amantadine (72;73), so NA inhibitors especially oral oseltamivir were the first
line of defense before the antigenically matched influenza vaccine became available. As a
result, the oseltamivir use reached unprecedented volume during the 2009 pandemic.
The scale and capability of monitoring of pH1N1 virus susceptibility to the NA
inhibitor by global and national institutions was also unprecedented in the history (73).
Since the detection of the pH1N1 viruses in April 2009, the first oseltamivir-resistant
pH1N1 virus was reported at Denmark at as early as August 2009, which carried the
common oseltamivir resistance marker NA H275Y mutation in N1 subtype and was
isolated from a patient receiving oseltamivir prophylaxis (72;74). Subsequently during
the pandemic, more sporadic oseltamivir-resistant variants have been isolated from
individuals receiving prophylaxis, from immunocompromised patients receiving
treatment, and from a few clusters of community isolates with no association to
oseltamivir use (73;75-78). As of October 2011, among more than 600 reported
oseltamivir-resistant variants (73), most of them are caused by the H275Y NA mutation,
with a few exceptions linked to other NA mutations, which are introduced below. The
low numbers of detected resistant variants indicate low prevalence of resistance in the
circulating pH1N1 viruses so far. Different surveillance studies reported from 0% ~ 3%
overall detection rate of resistant pH1N1 viruses varying from different periods and
regions (73;79;80). However, the isolation of community transmitted resistant pH1N1
viruses suggests that such viruses keep certain level of local transmissibility thus
reinforces the need for continual surveillance.
The pH1N1 viruses have the potential to become multi-NA inhibitor-resistant. In
the clinical isolates of the pH1N1 viruses, apart from than the common H275Y mutation
in the N1 subtype, several other NA mutations were firstly found in the N1 subtype of
NA genes which induce different level of resistance to NA inhibitors (73;77;81;82). The
NA I223R/I222R (N1/N2 numbering) mutation was identified in the clinical isolates of a
patient receiving oseltamivir treatment, and this mutation alone can reduce the pH1N1
virus susceptibility to all three NA inhibitors at a small degree (82). The I223R plus
H275Y double mutations future enhanced the resistant level to oseltamivir. Another form
of mutation I223V in the presence of H275Y mutation also has been identified in clinical
isolates (77), which further enhanced the resistance to oseltamivir and peramivir, but did
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not induced significant resistance to zanamivir (83) . The NA S247N mutation was
founded at high frequency (10~30%) in several clusters of community isolates of pH1N1
viruses (81). The S247N alone induced mildly reduced susceptibility to oseltamivir and
zanamivir, not to peramivir, and the S247N plus H275Y double mutations significantly
further enhanced the resistance level to oseltamivir, which have been found in clinical
isolates (81).
In view of the precedent example of the naturally resistant seasonal H1N1 viruses,
understanding the virus fitness of H275Y mutant resistant pH1N1 viruses in laboratory
based experiments were of special urgency under the pandemic context. Diverse isolates
of H275Y mutant pH1N1 viruses were subjected to extensive characterization and
assessment of infectivity and transmissibility in different animal models by individual
groups (84-88). The results across different studies reached some agreement on certain
conclusion that the H275Y mutant pH1N1 viruses had replication capability,
direct-contact transmissibility and overall virulence in animals similar or equivalent to
those of the wild-type viruses. However, these studies showed the biggest variation on
the transmissibility by respiratory droplet or aerosol route. Compared with their
respective wild-type viruses, two studies showed greatly reduced respiratory-droplet
transmissibility of two different H275Y resistant pH1N1 isolates in ferrets (84;86); one
study exhibited delayed respiratory-droplet transmissibility in one tested pH1N1 isolates
but essentially the same transmissibility in another isolate in ferrets (87); one study
observed the equivalent respiratory-droplet transmissibility of two reverse-genetics
derived H275Y mutant pH1N1 viruses in both ferrets and guinea pigs (88). Nevertheless,
these different results might be partly due to the various sources of pH1N1 viruses with
subtle different genetic backgrounds and different experimental settings. The fact that the
oseltamivir-resistant H1N1/2009 viruses remained certain level of transmissibility
underlines the necessity of continuous monitoring of drug resistance of circulating
pH1N1 viruses.
The clinical-derived NA inhibitor resistant pH1N1 viruses carrying the new
resistance mutations also raised the concern about their virus fitness. Some of the
resistant variants have been assessed for their fitness especially transmissibility relative to
wild-type viruses in experiments. Regarding to NA 223 mutation, one study showed that
an I223R mutant virus isolate has comparable replication ability and transmissibility but
lower pathogenicity in ferrets than the wild-type virus (89). Another study observed that
the virus infectivity and transmissibility in ferrets were comparable among the wild-type,
the H275Y only mutant and the I223V plus H275Y mutant pH1N1 viruses generated by
reverse genetics techniques (90). As regards to the NA S247N mutation, in a study using
reverse-genetics pH1N1 viruses in guinea pigs (91), the S247N mutation only virus
showed reduced respiratory-droplet transmissibility and the S247N plus H275Y double
mutation exhibited even further reduced transmissibility compared to the wild-type virus,
however, when the reverse-genetics pH1N1 virus were rescued from another NA genetic
background of pH1N1 virus, the S247N mutation only and S247N plus H275Y double
mutations caused the same reduced transmissibility compared to the wild-type virus.
These results suggest that the diverse NA genetic background can cause variation of the
virus fitness especially with the presence of the resistance-associated NA mutations.
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NA Inhibitor Resistance in Human Infection of Highly Pathogenic H5N1 Influenza
A Viruses
Highly pathogenic avian H5N1 viruses have special clinical relevance to human
beings. Since the first human cases in 1997 in Hong Kong (92), sporadic human infection
with highly pathogenic avian H5N1 influenza virus has been reported across Asia,
Europe, Africa and the Middle East (9). Human infection of highly pathogenic H5N1
virus exhibited severe pneumonia or acute respiratory distress syndrome with a mortality
rate higher than 60% (9;93). In view of that seasonal influenza vaccine does not have
effective cross reactivity again the H5N1 influenza viruses, the antiviral drugs especially
NA inhibitors are standing at the first line of defense of the H5N1 virus infection.
The NA inhibitor resistance in H5N1 viruses is a serious concern for public
health, thus the susceptibility of H5N1 virus has been evaluated and human infection of
H5N1 has been closely monitored. Phenotypic resistance test using H5N1 viruses from
south-east Asia showed that the viruses were generally sensitive to NA inhibitors but
with variability, depending on virus clades and isolation time (9;25). In human infection
of highly pathogenic H5N1 viruses, oseltamivir-resistant variants have been isolated from
patients receiving oseltamivir treatment or prophylaxis and resistance were associated
with two mutations H275Y or N294S at NA framework (9;94). Likewise in human N1
subtype viruses, the H275Y NA mutation in H5N1 viruses induced resistance to
oseltamivir and reduced susceptibility to peramivir but not to zanamiivir. The N294S NA
mutation was identified in one case of H3N2 human influenza virus previously (41), and
was only found in clinical isolates of H5N1viruses of N1 subtype so far (9;95), which
induced moderate resistance to oseltamivir. By far, the H275Y vairant were isolated from
3 cases during the N294S variant were isolated from 2 cases in Egypt (9;96;97). One
highly pathogenic H5N1 virus isolated from a patient treated with oseltamivir had a
mixed oseltamivir-sensitive and -resistant population, and the later were identified as
either H274Y or N294S NA mutations by plaque purification (97).
The infection of highly pathogenic H5N1 viruses in animal models exhibited
some special features different from human seasonal influenza viruses, such as extremely
high viral loads, systematic spread nature etc, high lethality etc (98). Especially, the
highly pathogenic H5N1 viruses can effectively infect mouse and cause lethality without
the need of prior adaptation like the human seasonal influenza viruses, making the mouse
model for useful evaluation of the virus fitness of H5N1 viruses. In both mouse and ferret
model, the reverse-genetics variants of a highly virulent strain A/Vietnam/1203/04 H5N1
virus carrying either the H275Y or N294S NA mutation retained their replication
efficiency and pathogenicity in vitro and in vivo similar to the wild-type H5N1 virus (99).
Also tested in both mouse and ferret models, the clinical-derived variants of
A/Hanoi/30408/2005 H5N1 virus carrying either the H275Y or N294S NA mutation
were attenuated in terms of pathogencity compared to the wild-type virus, with a bigger
degree of attenuation in the H275Y mutant than in the N294S mutant (97;100). It is
worth to note that both the H5N1 viruses both belong to HA clade 1 of H5N1 virus
phylogeny, but A/Hanoi/30408/2005 overall was less virulent than the
A/Vietnam/1203/04 virus in tested animal models (99;100). In a virus growth compitition
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experiment for direct comparasion of virus fitness in ferrets (101), as for a clade 2.2
H5N1 virus, the virus fitness of reverse-gnetics H275Y mutant of A/Turkey/15/2006-like
H5N1 virus was less than the wild-type virus, but regarding to a clade 1 H5N1 virus, the
virus fitness of the reverse-genetics H275Y mutant of A/Vietnam/1203/04 H5N1 virus
was equivalent to the wild-type virus, suggesting the virus fitness change of the resistant
H5N1 viruses were associated with the virus genetic background, other than the
resistance markers.
Concluding Remarks
The development of NA inhibitor resistance is a huge drawback to the control of
influenza infection by antiviral drugs. The experimental studies of the NA
inhibitor-resistant influenza viruses of different type/subtypes have significantly
advanced our understanding of the molecular mechanism of the resistance, change of
virus fitness in the resistant viruses. These studies have exerted significant implications
on surveillance monitoring of susceptibility of circulating influenza viruses to NA
inhibitors. On the other hand, some different studies of fitness of the resistant virus of a
same resistance marker reached disparate conclusions towards their clinical relevance.
The reasons for such discrepancy could be simply from the virus variants used, or the
different animal models tested or the diverse experiment setting used. The different
genetic backgrounds of the viruses could be subtle difference in NA gene contexts such
as in the naturally resistant H1N1 viruses vs the drug-induced resistant H1N1 viruses, or
could be in the genome such as in the highly pathogenic H5N1 viruses of different clades.
The further advancement of understanding molecular mechanism of fitness of NA
inhibitor-resistant viruses necessitates combination of multiple parameters at different
levels from viral genes to viral proteins to viruses. The risk of emergence of NA
inhibitor-resistant influenza viruses with undiminished fitness should be an alert for
surveillance monitoring and experimental studies of circulating influenza viruses.
Overall, NA proteins play an essential role in influenza A virus infection in hosts,
and the use of NA inhibitors for treatment of influenza virus infection has induced
resistant viruses with different NA mutations. Consequently, how the resistance
associated mutations affect NA function and fitness of the mutant influenza viruses
remain a big question and are subject for further investigation. In the following two
chapters, two studies investigated the impacts of an oseltamivir resistance-associated
mutation (NA H275Y) in the 2009 pandemic H1N1 virus or the seasonal H1N1 virus
background on the virus in vitro and in vivo fitness including transmissibility. These
studies aim to evaluate and understand resistant-virus fitness by integrating multiple
parameters at different levels from genes to proteins to viruses. The related backgrounds,
specific questions and aims of each study are introduced separated in each chapter.
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CHAPTER 2. THE VIRUS FITNESS AND TRANSMISSIBLITY OF AN
OSELTAMIVIR-RESISTANT 2009 PANDEMIC H1N1 INFLUENZA A
VIRUS*
Introduction
A novel swine-origin H1N1 influenza virus emerged in Mexico in April 2009 and
rapidly spread worldwide, causing the first influenza pandemic of the 21st century (6;7).
Most confirmed human cases of H1N1/2009 influenza have been uncomplicated and mild
(102), but the increasing number of cases and affected countries warrant optimal
prevention and treatment measures. At present, two classes of antiviral drugs are
approved for specific management of influenza: M2-ion channel blockers (amantadine
and rimantadine) and neuraminidase (NA) inhibitors (zanamivir and oseltamivir).
However, variants resistant to both classes of drugs have emerged. During the 2007-2008
season, most circulating seasonal H3N2 influenza viruses, and H1N1 viruses in certain
geographic areas, were reportedly resistant to M2-blockers (103;104); today, almost all of
the pandemic H1N1/2009 viruses tested are resistant to M2-blockers (72). Therefore,
only the NA inhibitors are currently recommended for treatment of influenza (105).
The NA-inhibitor resistance-associated mutations in influenza viruses are
drug-specific and NA subtype-specific (106). Until 2007, the clinical data indicated only
sporadic, rare emergence of oseltamivir resistance under drug selection pressure (< 1% in
adults and 4%-8% in children) (41;107;108). Later reports observed increased frequency
of oseltamivir-resistant variants (16 % and 27%) in drug-treated children (47;108). The
situation changed dramatically during the 2007-2008 season, when seasonal H1N1
influenza viruses with the common oseltamivir-resistance NA H275Y mutation (275 in
N1 numbering, 274 in N2 numbering) became widespread in first the northern (109) and
then the southern (59) hemispheres. It remains uncertain where these naturally resistant
H1N1 influenza viruses originated and how they acquired optimal fitness and
transmissibility, but the resistant variants were clearly becoming the dominant strain at
the time the swine-origin pandemic H1N1/2009 virus emerged (45;56;60). During the
H1N1/2009 influenza pandemic, to date, almost all tested viruses have remained
susceptible to oseltamivir and zanamivir (72), but oseltamivir-resistant variants with
H275Y NA mutation have been isolated from individuals receiving prophylaxis (77;110)
and from immunocompromised patients (76) under drug selection pressure.
Oseltamivir-resistant variants also have been isolated from untreated patients (111;112)
and from a few community clusters (75;113;114), including two suspected cases of
nosocomial transmission among immunocompromised patients (75;114), although it is
uncertain whether the mutants came from secondary transmission or arose spontaneously.
The
* Chapter 2 adapted with permission. Duan,S., Boltz,D.A., Seiler,P., Li,J., Bragstad,K.,
Nielsen,L.P., Webby,R.J., Webster,R.G., and Govorkova,E.A. 2010.
Oseltamivir-resistant pandemic H1N1/2009 influenza virus possesses lower
transmissibility and fitness in ferrets. PLoS. Pathog. 6:e1001022.
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isolation of resistant H1N1/2009 viruses with no link to oseltamivir use raised serious
concern that these viruses might acquire fitness and spread worldwide, as had
oseltamivir-resistant seasonal H1N1 viruses during 2007-2008 season.
The increasing concern about oseltamivir-resistant H1N1/2009 viruses prompted
us to evaluate transmissibility and growth fitness of one oseltamivir-resistant variant. The
infectivity and transmissibility (and thus the clinical relevance) of several NA
inhibitor-resistant influenza viruses have previously been studied in experimental animal
models (51;52;115;116). These studies differed in the influenza A subtypes studied
(H1N1, H3N2, or H5N1), the NA mutations involved (H275Y, R292K, E119V or
I222V), the animal model used (ferret or guinea pig), and the transmission routes studied
(direct contact and respiratory droplets); in these studies, the transmissibility of most of
the NA inhibitor-resistant influenza viruses was to some extent less efficient. Here we
characterized in vitro and in a ferret model a pair of pandemic H1N1/2009 clinical
isolates. The pandemic A/Denmark/524/09 (A/DM/524/09) and A/Denmark/528/09
(A/DM/528/09) viruses were isolated from a small cluster of patients with H1N1/2009
virus infection. The A/DM/528/09 virus, carrying the H275Y NA mutation, was isolated
from a patient on oseltamivir prophylaxis, and its ancestor is likely to have been
A/DM/524/09 virus. By recapitulating two natural routes of influenza virus transmission
in ferrets, we found that the oseltamivir-resistant virus was less transmissible than its
sensitive counterpart through the respiratory droplet route but retained efficient
transmission through direct contact.
Results
Sequencing and Phylogenetic Analysis of NA Genes
Sequence analysis of the NA genes revealed that A/DM/524/09 virus encoded a
conserved H residue at amino acid position 275, whereas A/DM/528/09 virus had an
H275Y amino acid mutation caused by a single T-to-C nucleotide substitution at codon
275 (Table 2-1). Pairwise sequence analysis of the full viral genomes showed that the
A/DM/524/09 and A/DM/528/09 viruses had no amino acid differences other than the
H275Y NA mutation and were a highly matched pair. Sequence analysis and
phylogenetic analysis of the two viruses NA and HA genes (data not shown) confirmed
that the wild-type A/DM/524/09 and mutant A/DM/528/09 viruses belonged to the
swine-origin 2009 pandemic virus lineage. The alignment of the NA and HA sequences
showed that viruses with H275Y NA substitution have some amino acid differences from
certain wild-type viruses (without H275Y NA mutation), but these differences also were
observed in other wild-type viruses. Comparison of the NA and HA amino acid
sequences of A/DM/528/09 virus with sequences of other 24 H275Y mutants and around
2000 wild-type H1N1/2009 viruses available in Gene Bank did not reveal an increased
frequency of any specific amino acid mutation(s) shared among the viruses analyzed
(data not shown).

19

Table 2-1. Neuraminidase enzymatic properties of the H1N1 influenza viruses.

H1N1 viruses

Sequence at NA
position 275
Nucleotide Amino acid

NA enzyme inhibition
IC50 ±SDa (nM)

Enzyme kineticsb

Oseltamivir
carboxylate

Zanamivir

Km (μM)

Vmax
(U/sec)

Pair 1 (pandemic)
A/Denmark/524/09

CAC

H

5.0±0.8

1.3±0.15

55.1±4.2

101.6±7.9

A/Denmark/528/09

TAC

Y

972±283*

1.0±0.13

80.3±6.0*

86.8±5.6*

A/Brisbane/59/07

CAT

H

6.2±0.6

1.0±0.1

23.7±1.7

66.5±11.2

A/New Jersey/15/07

TAT

Y

1546±327*

1.4±0.1

35.0±2.8* 37.4±13.5*

Pair 2 (seasonal)

a

The full genomes of both viruses were sequenced; only differences are shown. In order of segments, the GenBank accession
numbers are CY043339 - CY043346 for A/DM/524/09 virus and CY043347 - CY043354 for A/DM/528/09 virus genome
sequences.
b
Mean ± SD from five independent measurements. Assayed in parallel with reference A/Fukui/08/02 (H3N2) virus. Km and
Vmax values were derived from the Michaelis-Menten plot.
* P<0.05 compared to value for respective wild-type virus.
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NA Inhibitor Susceptibility and NA Enzyme Kinetics
To assess the NA inhibitor susceptibility of the two viruses, we performed NA
enzyme inhibition assays with the NA inhibitors oseltamivir carboxylate (active
metabolite of oseltamivir) and zanamivir. The wild-type A/DM/524/09 virus was
susceptible to oseltamivir carboxylate (mean IC50: 5.0 nM), but the A/DM/528/09
carrying the H275Y NA mutation had IC50 values approximately 200 times that of the
wild-type virus (Table 2-1). The IC50 of zanamivir was comparable for both viruses and
was uniformly low (mean IC50  1.3 nM) (Table 2-1). These results showed that the
H275Y NA mutation conferred resistance to oseltamivir carboxylate but did not alter
susceptibility to zanamivir.
To understand the impact of the H275Y mutation on the NA enzymatic properties
of the H1N1/2009 viruses, we determined the NA enzyme kinetics of both viruses. Km is
an estimate of the dissociation equilibrium for substrate binding to enzyme and the
reciprocal of Km approximates the affinity of substrate binding, while Vmax reflects the
enzyme’s catalytic activity. The NA of resistant A/DM/528/09 virus had a slightly higher
Km and lower Vmax than the NA of the sensitive A/DM/524/09 virus (Table 2-1). The
H275Y NA mutation reduced NA affinity for substrate and NA catalytic activity,
although the function of NA was not severely impaired. This finding in the H1N1
pandemic virus is similar to that reported by another group, in which NA enzymatic
function was not impaired in some naturally resistant seasonal viruses isolated during the
2007 season (117). Our study is the first to show reduced but not severely impaired NA
enzymatic function in a resistant H1N1/2009 virus with the H275Y mutation.
Plaque Morphology and Growth Kinetics in Cells
To determine whether the H275Y NA mutation affects virus growth in vitro, we
characterized virus plaque morphology and growth kinetics in both MDCK and
MDCK-SIAT1 cells. The latter have increased surface expression of human-like
Į2,6-linked terminal sialic acids (118) and may better assess the growth capability of
human influenza viruses. In MDCK cells, both pandemic H1N1/2009 viruses formed
pinpoint-like (0.3 mm) plaque phenotype (Fig 2-1A), differing significantly from some
seasonal H1N1 viruses, such as A/Brisbane/59/2007 (BR/59/07) virus, which formed
large plaques (1.3 mm) (P<0.05) (data not shown); however, the plaque size did not differ
between the oseltamivir-sensitive and -resistant viruses (Fig 2-1A), indicating that the
H275Y NA mutation did not alter plaque morphology. In MDCK-SIAT1 cells, both the
pandemic viruses and seasonal BR/59/07 (data not shown) formed only pinpoint-like
plaques (Fig 2-1B), consistent with a previous report (118) that this cell line did not
generate clear plaques for influenza viruses.
To further evaluate the impact of the H275Y NA mutation on virus growth in
vitro, we performed single- and multiple-cycle growth studies of both viruses in MDCK
and MDCK-SIAT1 cells. In single-cycle growth in the two cell lines, the two viruses
reached comparable levels 6 hours post-infection, but the initial growth of the
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Figure 2-1. Plaque morphology and replication kinetics of two H1N1/2009 influenza
viruses in MDCK and MDCK-SIAT1 cells.
The diameters of 20 randomly selected value plaques were measured in MDCK cells (A)
and MDCK-SIAT1 cells (B). Values are mean (± SD) plaque diameter (mm).
Single-cycle (C, D left panel) and multiple-cycle (C, D right panel) growth curves were
obtained by using an MOI of ~2 and ~0.001 PFU/cell, respectively. Virus in the
supernatant was titrated in MDCK or MDCK-SIAT1 cells and expressed as
log10TCID50/ml at the indicated time post-infection. Each point represents the mean
log10TCID50/ml ± SD from three experiments. * P<0.05 compared to value for wild-type
viruses.
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oseltamivir-resistant virus was significantly delayed in comparison to its sensitive
counterpart (P<0.05) (Fig 2-1C): at 4 hours post-infection, the yield of resistant viruses
was at least 1 log10TCID50/ml lower (P<0.05). Likewise, in multiple-cycle growth, the
two viruses reached comparable yields 24 hours post-infection, but the resistant virus
showed a significant growth delay during the first 12 hours post-infection (P<0.05); this
delay was more conspicuous in MDCK-SIAT1 cells than in MDCK cells (Fig 2-1D),
probably because overexpressed Į2,6 receptors on cell surface could better differentiate
NA’s function in support of viral growth. Therefore, final virus yields of
oseltamivir-resistant pandemic virus in the MDCK and MDCK-SIAT1 cells were not
altered, but their growth at the initial infection stage was significantly delayed.
Transmissibility among Ferrets via Direct-contact and Respiratory-droplets Routes
The transmissibility of pandemic H1N1/2009 viruses was studied in a ferret
model. Two naïve ferrets were housed at day 2 post-inoculation (p.i.) in the same cage
with one inoculated ferret (direct contact), and two naïve ferrets were placed in an
adjacent cage separated from the donor’s cage by two layers of wire mesh (respiratory
droplet exposure). Transmission of H1N1 virus was assessed by detection of infection in
recipient ferrets (nasal wash titers, clinical signs, and seroconversion). Virus samples in
nasal washes at day 4 p.i. or post-contact (p.c.) were sequenced to detect the presence of
the H275Y NA mutation.
The donor ferret inoculated with oseltamivir-sensitive A/DM/524/09 virus shed
virus until day 6 p.i. (Fig 2-2A, Table 2-2). Two of 2 direct-contact ferrets and 1 of 2
respiratory droplet-exposed ferrets were infected through virus transmission, as indicated
by the virus titers and inflammatory cell counts in their nasal washes (Fig 2-2) and by
seroconversion (Table 2-3). Virus shedding and nasal inflammation began earlier in the
direct-contact ferrets, suggesting that transmission through respiratory-droplets may have
a greater lag time. One respiratory droplet-exposed ferret showed no detectable virus
shedding or inflammation, but its post-contact serum had a positive HI titer (320).
Although seroconversion indicated infection in this ferret, the time of infection could not
be determined and therefore we could not attribute the infection to direct contact with the
co-caged ferret versus respiratory droplet transmission from the adjacent cage.
The donor ferret inoculated with oseltamivir-resistant A/DM/528/09 virus shed
virus until day 8 p.i. (Fig 2-2), with a peak virus titer comparable to that of A/DM/524/09
virus (Table 2-2). Two of 2 direct-contact ferrets were infected through transmission (Fig
2-2), but neither respiratory droplet-exposed ferret was infected, as confirmed by the
absence of seroconversion (Table 2-3). These results showed that the resistant H275Y
mutant A/DM/528/09 virus was transmitted efficiently only by direct contact. Virus
shedding in two direct-contact ferrets was lower and peaked after a longer interval in this
group than in the oseltamivir-sensitive A/DM/524/09 group (Fig 2-2A), although the
severity and course of disease were similar (Fig 2-2B, Table 2-3).
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Figure 2-2. Transmissibility of the two H1N1/2009 influenza viruses among ferrets.
The virus titer (A, B left panel) and total number of inflammatory cells (A, B right panel)
in the nasal wash samples from each donor ferret, direct-contact (DC contact) ferret, and
respiratory droplet-contact (RD contact ) ferret. The arrow indicates the first day of
exposure of contact ferrets.
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Table 2-2. Clinical signs, virus replication and sero-conversion in inoculated donor ferrets.
Inoculated donor ferretsa
Clinical signs

H1N1 virus
Weight
lossb (%)

Virus replication

Sneezing
Last day
(day of
of
onset) inflammationc

Peak virus Last day
Serum
of
titer
HI
titerf
(day p.i)d sheddinge

A/Denmark/524/09

5.0 (2)

3

12

7.3 (2)

6

1280

A/Denmark/528/09

6.2 (2)

7

12

6.9 (2)

8

640

Co-inoculationg

5.9 (4)

7

12

7.7 (2)

6

640

a

n=1 for each virus group.
The maximum percent weight loss during the 21 days p.i. Numbers in parentheses indicate the day of maximum weight loss.
c
Upper respiratory tract inflammation was defined as a total inflammatory cell count  10 times the baseline count.
d
Virus titers in nasal washes (log10TCID50/ml).
e
The first day of observation on which virus was not detected.
f
Hemagglutination inhibition (HI) antibody titers to homologous virus 21 days p.i.
g
Co-inoculation of ferret with A/DM/524/09 and A/DM/528/09 viruses at 1:1 ratio.
b
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Table 2-3. Clinical signs, virus replication, and seroconversion in contact ferrets.
Direct contact
H1N1 virus

Clinical signs
Weight
Sneezingb
lossa

Respiratory droplets

Virus detection
Virus
sheddingc

Last day
of
sheddingd

A/Denmark/524/09

2/2
(3.5)

1/2
(7)

2/2
(8.3)

8, 8

A/Denmark/528/09

2/2
(3.3)

2/2 (5,7)

2/2
(7.0)

8, 10

Co-inoculation f

2/2
(6.0)

1/2
(2)

2/2
(7.1)

10, 10

a

Clinical signs
Serum
HI
titere
1280,
640

Weight
Sneezingb
lossa

Virus detection
Virus
sheddingc

Last day Serum
of
HI
d
shedding titere
1280,
10
320

1/2
(6.0)

1/2
(7)

1/2
(7.2)

1280,
1280

0/2

0/2

0/2

NA

<10,
<10

1280,
1280

NA

NA

NA

NA

NA

Number of animals with weight change/total number (maximum percent weight loss during the 21 days p.c.).
Number of animals sneezing/total number during the 21 days p.c. (day of observed onset).
c
Number of virus-shedding animals/total number. Numbers in parentheses indicate mean peak virus titer (log10TCID50/ml) in
nasal wash samples).
d
The first day of observation on which virus was not detected.
e
Hemagglutination inhibition (HI) antibody titers to homologous virus in ferret serum on day 21 p.c.
f
Donor ferret was co-inoculated with A/DM/524/09 and A/DM/528/09 viruses at a 1:1 ratio.
b
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We verified the sequence stability of the NA at position 275 in each virus after
replication and transmission in ferrets. Direct sequencing of the NA genes from nasal
wash samples revealed no sequence change at this position in either virus (data not
shown). Therefore, no spontaneous H275Y NA mutation emerged in the wild-type virus
and the H275Y mutation remained stable in the mutants after transmission to a new host.
Co-inoculation with Oseltamivir-sensitive and -resistant H1N1/2009 Viruses
Because both the oseltamivir-sensitive and the oseltamivir-resistant H1N1/2009
viruses were efficiently transmitted by direct contact, hosts could potentially be exposed
to both types of virus. To compare the relative growth capability and transmissibility of
the sensitive and resistant H1N1/2009 viruses within the host, we co-inoculated a ferret
with a 1:1 ratio of the sensitive A/DM/524/09 and resistant A/DM/528/09 viruses. The
pattern of virus shedding and the clinical signs were similar to those in ferrets inoculated
with either A/DM/524/09 or A/DM/528/09 virus (Fig 2-3A). By using a relative
quantification of single nucleotide polymorphism (SNP) method to detect the NA
genotype at codon 275 (CAC or TAC), we found that the virus population in the
co-inoculated ferret’s nasal washes remained mixed but was predominantly a wild-type
(oseltamivir-sensitive) population (Fig 2-3B). The proportion of wild-type virus in the
nasal wash increased progressively, from 75% on day 1 p.i., to almost 100% on day 6 p.i.
(Fig 2-3B). Two of 2 ferrets placed in direct contact with the co-inoculated ferret were
infected through transmission (Fig 2-3A). SNP analysis of their nasal wash samples
showed only wild-type virus (Fig 2-3B). In summary, the oseltamivir-sensitive
A/DM/524/09 virus possessed greater growth capability in the upper respiratory tract
than did resistant A/DM/528/09 virus and thus had an advantage in direct-contact
transmission.
Discussion
This study is the first, to our knowledge, to demonstrate the inefficient respiratory
droplet transmission of an oseltamivir-resistant H275Y mutant of H1N1/2009 in ferrets,
which are an established animal model of the pathogenesis and transmission of human
influenza viruses. The oseltamivir-resistant mutant virus retained efficient transmission
only by direct contact, whereas the oseltamivir-sensitive pandemic virus was efficiently
transmitted by both routes. These results show that the transmissibility of the
oseltamivir-resistant H1N1/2009 influenza virus had been altered. We suggest that the
lower fitness of oseltamivir-resistant variant within the host along with its reduced NA
enzyme efficiency and delayed growth of the H275Y mutant virus in vitro may at least in
part explain its impaired transmission among ferrets.
There are limited experimental data about the routes of transmission of
oseltamivir-resistant influenza viruses. The two natural routes of influenza virus
transmission, direct contact with fomites and respiratory droplets (aerosol and larger
droplets (119), are not mutually exclusive. Therefore, the transmissibility of influenza
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Figure 2-3. Co-infection with oseltamivir-sensitive and -resistant H1N1/2009
influenza viruses.
Virus titers and inflammatory cell counts in the nasal wash specimens of ferrets
co-inoculated with oseltamivir-sensitive and -resistant H1N1/2009 viruses (A). The arrow
indicates the first day of exposure of contact ferrets. The proportion of wild-type virus (C
in SNP sequence) in the mixed virus population (C+T in SNP sequence) in nasal wash
samples from the donor ferret and two direct-contact ferrets (B). Values are the mean ±
SD from three independent measurements. * P<0.05 compared to value for day 0 p.i.
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viruses via both routes must be investigated if the results are to be clinically relevant. In
the earliest studies, oseltamivir-resistant H3N2 (R292K NA mutant) and H1N1 (H275Y
NA mutant) variants exhibited severely compromised replication and virulence both in
vitro and in vivo (54;55) and were therefore thought unlikely to be of clinical
consequence. In a subsequent study, an R292K mutant of H3N2 virus was not transmitted
by direct contact among ferrets (52). Under similar conditions, the transmission of an
E119V mutant of H3N2 virus and an H275Y mutant of A/New Caledonia/20/99-like
H1N1 virus by direct contact required a higher dose of inoculum than transmission of the
wild-type viruses, and it occurred more slowly (120). However, none of these studies
assessed both routes of transmission. The only study to date that has evaluated both
routes of transmission of oseltamivir-resistant virus showed that recombinant resistant
H3N2 viruses with either the E119V or the E119V+I222V NA mutation were transmitted
efficiently by direct contact but not by respiratory droplets among guinea pigs (51). Our
study is a latest addition to the previous data by comparing a highly matched pair of
H1N1/2009 viruses and by assessing the transmissibility of resistant viruses via two
routes in ferrets.
The reduced transmissibility of the oseltamivir-resistant H1N1 viruses could be
explained by a number of factors (121-123). First, host physical exposure to virus is
directly affected by the quantity of virus shed into the environment. In our study,
inoculated donor ferrets shed comparable quantities of both viruses, which indicated
potential comparable environmental contamination in the restricted space of cages;
therefore, it is unlikely that transmission was affected by the level of donor viral
shedding. Other host variables such as the extent of inflammation could affect the amount
and size of upper respiratory secretions thus the release of infectious respiratory droplets.
For example, sneezing, a common host symptom believed to mediate viral transmission,
was observed only at later stages in the ferret inoculated with resistant virus, when
inflammation was more severe but virus shedding had declined greatly. Second, efficient
transmission to a naive host requires not only viral exposure but also successful viral
invasion, effective replication and simultaneous evasion of the first line of host innate
immunity (124). Our results showed a significant initial growth delay in two cell lines of
the resistant virus. This growth delay could be caused by delayed release of progeny
virions from the host cell surface due to reduced NA enzyme efficiency observed in the
resistant virus. Such a delay would not affect the final virus yield in cell lines, but in the
respiratory tract of ferrets it could allow the host’s first-line innate immune defense (e.g.,
macrophages or neutrophils) sufficient time to clear the virus. The NA enzyme also
facilitates virus binding, entry, and spread within the host by removing terminal
sialic-acid residues from mucus and preventing virion self-aggregation (25), and
therefore the NA mutation could have affected viral penetration into the host respiratory
tract. The slightly reduced (not severely impaired) NA enzyme function and delayed viral
growth of the H275Y mutant may have been more crucial in recipient ferrets that
acquired virus from environment via natural routes than in donor ferrets inoculated with a
high dose of virus, as we observed delayed viral shedding or inefficient transmission in
the recipient ferrets, but not in the inoculated donor ferret.
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Although the transmissibility of the oseltamivir-resistant H1N1/2009 virus was
reduced by the H275Y NA mutation, the severity and course of disease was similar to
that caused by oseltamivir-sensitive H1N1/2009 virus in both inoculated and
direct-contact ferrets, with no apparent attenuation of clinical signs. In inoculated ferrets,
the viruses showed comparable replication in the upper respiratory tract and caused
comparable clinical signs, including weight loss and inflammation. However, one caveat
to ferret model has been noticed that high inoculation dose may mask the differential
viral replication and clinical signs for different viruses (125). In the direct-contact ferrets,
which acquired virus though natural routes, the shedding of resistant virus peaked later
than the shedding of susceptible virus, but the duration of shedding and the severity of
disease was not compromised when compared with sensitive virus. Therefore, the H275Y
mutant of pandemic H1N1/2009 virus is likely to be of clinical consequence in humans.
The fitness of a virus describes its relative ability to produce infectious progeny in
a host (39). Competitive growth assay by co-infection is a method of evaluating the
growth fitness of two viruses (39;126). In the present study, we inoculated a ferret with
equal doses of oseltamivir-sensitive and -resistant H1N1/2009 viruses to compare their
relative growth fitness within the host. The mixed virus population in the nasal wash was
analyzed at different days p.i. to determine which viral genotype predominated. To
bypass the time- and labor-intensive process of cloning the desired genes from the mixed
populations and choosing an arbitrary number of clones for genotypic analysis, we used a
new method, relative quantification of SNP, to determine the ratio of wild-type to mutant
populations. This method showed high reproducibility in genotyping HIV protease gene
(126). Our study is the first to use this method to genotypically analyze influenza viruses.
For the H1N1/2009 influenza viruses, we designed a specific probe to detect the first
nucleotide of codon 275 of the NA gene, where a single C-to-T substitution causes an
H-to-Y amino acid substitution. Our results showed that the oseltamivir-resistant mutant
H1N1/2009 virus possessed less growth fitness than the sensitive H1N1/2009 virus in the
ferret upper respiratory tract. At least partly for that reason, only wild-type H1N1/2009
virus was transmitted to the direct-contact ferrets. The competitive transmission
advantage of wild-type H1N1/2009 virus should be confirmed by other types of
experiments.
In summary, our study determined the comparative transmissibility of a pair of
naturally circulating oseltamivir-sensitive and oseltamivir-resistant H1N1/2009 viruses.
This information from this study could be useful in assessing the clinical relevance of
contemporary pandemic viruses, considering the extensive use of oseltamivir during this
pandemic. The H275Y mutant of H1N1/2009 used in this study was the first
oseltamivir-resistant H1N1/2009 isolate from a patient on oseltamivir prophylaxis. As
this study was undertaken, additional H275Y mutants of H1N1/2009 viruses have
emerged in the absence of oseltamivir use (114;127). The emergence of these viruses
should raise concerns as to whether resistant H1N1/2009 viruses will acquire
significantly greater fitness and spread worldwide as did the naturally resistant H1N1
viruses during the 2007-2008 season. Further studies of these newly isolated H275Y
mutants of H1N1/2009 viruses are warranted to determine whether they have acquired
additional changes.
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CHAPTER 3. THE MOLECULAR BASIS OF NATURALLY-OCCURRING
OSELTAMIVIR-RESISTANT H1N1 INFLUENZA A VIRUSES
Introduction
The neuraminidase (NA) inhibitors (oseltamivir and zanamivir) are among the
first line of defense against influenza infection. At present, two classes of antiviral drugs
are approved for specific management of influenza: M2-ion channel blockers
(amantadine and rimantadine) and neuraminidase (NA) inhibitors (zanamivir and
oseltamivir) (28). However, variants resistant to both classes of drugs have emerged.
Since 2007 season, most circulating seasonal H3N2 influenza viruses, varying portions of
seasonal H1N1 viruses and avian influenza viruses of different subtypes, and almost all
tested 2009 pandemic H1N1 viruses were reportedly resistant to M2-blockers (29;73).
Therefore, only the NA inhibitors are currently recommended for treatment of influenza.
The resistance to NA inhibitors can significantly limit the infection control
options for influenza, so the susceptibility of circulating human influenza viruses to NA
inhibitors has been closely monitored. Since the NA inhibitors were approved for clinic
use in 1999, the resistant variants had emerged and the resistance detection rates had a
radical change over the past decade (42;45;56). Until 2007, both the clinical observations
and surveillance data indicated only sporadic, rare detection rate of resistance to NA
inhibitor mainly under drug selection pressure (41;46;48), suggesting extremely low
prevalence of resistance among circulating influenza viruses and no evident transmission
of resistant viruses. However, the situation changed dramatically during the 2007-2008
season, when seasonal H1N1 influenza viruses carrying the common
oseltamivir-resistance NA mutation H275Y (274 in N2 numbering, 275 in N1 numbering)
were detected with high prevalence in first the northern (57;58) and then the southern
hemispheres (59) with no link to oseltamivir use. In the early 2009 season, almost 100%
of H1N1 virus isolates tested in the USA were found to carry this resistant marker (60).
The resistant variants were clearly becoming the dominant strain until the 2009 H1N1
pandemic took over the world (56;128). Naturally-occurring oseltamivir-resistant or
naturally resistant H1N1 viruses have been used to specifically refer to these seasonal
H275Y mutant resistant H1N1 variants which were detected under the contexts of
absence of oseltamivir use during the 2007~2009 seasons, in differentiation with the
drug-selected viruses isolated from patients treated with NA inhibitors.
It has remained puzzling for a long time how these naturally-resistant H275Y
mutant viruses acquired optimal fitness because the previous experimental and
epidemiologic data suggested otherwise (54;55). Two pioneering works on the naturally
H275Y mutant H1N1 viruses significantly advanced the understanding to this question
from two different angles (67;68). The visionary work by M.A Rameix-Welti et al (68),
for the first time, revealed the distinct level of NA enzyme affinity and distinct cluster
patterns of NA and HA genes of wild-type and H275Y mutant viruses among the older
and new isolates of seasonal H1N1 viruses. In line with this study, subsequently, some
phylogeny studies classified the specific cluster patterns of the NA and HA genes as
different clades and showed the same trends that vast majority of H275Y mutant H1N1
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viruses, especially the naturally resistant ones, commonly belonged to the Clade 2B (6266). Further studies have associated the higher enzyme affinity in some Clade 2B viruses
to certain NA amino acid substitutions (63;69) and one study confirmed the role of NA
D344N substitution in NA enzyme affinity (70). Another pioneering work by Bloom J. D
et al (67), for the first time discovered that surface accumulation of a NA protein was
reduced by the H275Y mutation and this defect could be corrected by two permissive
mutations Q222R and V234M which appeared prior to the H275Y mutation in the NA
evolution. This study is of significance to be the first to move the understanding of the
defect by the H275Y mutation to NA protein expression level and firstly proposed the
concept for the “permissive” mutations for H275Y mutation from the perspective of gene
evolution. Following this findings, a recent study confirmed that the substitutions of the
identified “permissive” residues into the “unpermissive” residues in the NA gene of a
recent Clade 2B virus compromised the H275Y mutant virus replication in vitro and in
vivo (71).
These studies have provided insights to understand the defects in NA protein and
virus caused by the H275Y NA mutation and how permissive NA mutations can
counteract such defects in NA protein. However, because NA proteins play essential roles
in influenza virus normal life cycle, it has been hypothesized that the permissive
mutations may not only restore the defect caused by the H275Y mutation, but also may
have extended roles beyond what were seen in H275Y mutant viruses (129). A simple but
fundamental question remains open: what were the potential fundamental changes in the
of seasonal H1N1 viruses other than H275Y mutant viruses during the first decade of
oseltamivir use. So far no study had been done to learn about the wild-type H1N1 viruses
themselves including NA protein function in vitro and virus fitness in vivo.
This present study had started with aims to systematically characterize the virus
fitness in vivo and NA phenotypes in vitro of genetically divergent seasonal H1N1
viruses based on the NA phylogeny, also to comprehensively assess which and how the
NA amino acid substitution in the NA gene divergence can affect the phenotype. To our
surprise, the two “permissive mutations” enabling the H275Y mutation was consistent
with our results but two mutations were only half of the growing list of permissive
mutations, and even the “permissive mutations” for the H275Y mutation was only part of
the whole story of NA protein evolution. Our results revealed that the natural NA genetic
divergence led to significant phenotypic changes of the NA proteins themselves at many
aspects, which in return determined the differential effects of the H275Y mutation on the
NA proteins. Further study in combination with timeline analysis of the fixation of the
divergent NA amino acid residues allow us to proposed a scenario for emergence of the
naturally resistant viruses: during the seasonal H1N1 virus evolution, there were
subsequent two lineages of H1N1 viruses with NA proteins of distinct attributes at
protein level; the H275Y mutation had detrimental effects on protein expression and
function of the old lineage NA proteins, which it only caused a minimal negative effects
on the new lineage NA proteins; as results, the H275Y mutant H1N1 viruses of old
lineage were extinguished due to severely compromised virus fitness, while the H275Y
mutant viruses of new lineage were kept in continuing circulation due to minimally
altered virus fitness – the naturally resistant H1N1 viruses.
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Results
Evolution of NA Genes of Seasonal H1N1 Influenza Viruses
We firstly assessed the overall genetic difference of the NA genes of seasonal
H1N1 viruses by examining their evolution history with a focus on NA H275Y variants
isolated from 1999 to 2009 season. The phylogenetic analysis shows that the NA genes
between 1999~2009 can be classified into four distinct lineages (Fig 3-1): New
Caledonia/20/99-like (NC99-like), Solomon Island/23/06-like (SI06-like),
Brisbane/59/07-like (BR07-like), and /Colorado/UR06-0053/2007 (CO07-like),
corresponding to the classification of Clade1, Clade2A, Clade2B, Clade2C in previous
reports (63-66). The tree also shows that the vast majority of NA H275Y variant isolates
accumulate at the BR07-like lineage, and only a few H275Y isolates sparsely scatter at
the NC99-like lineage (Fig 3-1). This observation is consistent with the previous
surveillance studies of NA inhibitor susceptibility (63-66). To find the essential
underlying difference between the two lineages, we compared the NA consensus
sequences of both wild-type and H275Y mutant viruses from the BR07-like and
NC99-like lineages. The comparison revealed that apart from the resistance-associated
H275Y mutation, there are only ten amino acid residues substitutions differentiating the
NA genotype between the BR07-like and NC99-like lineages (Table 3-1). It is
noteworthy that there is one predominant amino acid substitution (D354G) between the
NA genes of wild-type and H275Ymutant viruses within the BR07-like lineage, and it is
a reversion of the G354D substitution between the NC99-like and BR07-like lineages.
We mapped the positions of the ten amino acid residues into a N1 molecule structure (Fig
3-2), and found that none of them are located at the NA enzyme active site. The position
45 and 78 are located at stalk region of NA molecule (not shown in the structure view);
the position 222, 234, 249 and 344 are located on the periphery of the active site, and the
position 214, 287, 329, 354 are located more distant from the active site.
In order to reveal if there are any fundamental differences in the phenotypes of the
H1N1 viruses, we then selected certain wild-type and H275Y mutant viruses from both
the BR07-like and NC99-like lineages for subsequent characterization in vivo and in
vitro. We chose viruses of NA genes of different molecular features for further
comparison, with some being totally in agreement with the corresponding consensus
residues at the ten positions and some possessing non-consensus residues at one or two
positions. The alignments of the NA protein sequences of the selected H1N1 viruses with
their corresponding consensus amino acid residues at ten positions are listed (Table 3-2).
For example, the wild-type BR/59/07 and MEM/13/06 viruses, and the H275Y mutant
NY/1692/09 and GA/20/06 viruses are fully in agreement with their corresponding
consensus residues at all ten positions; while H275Y mutant HW/28/07, NY/3467/09,
MI/03/02 viruses differ in their corresponding consensus residues at one or two positions
respectively.
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Figure 3-1. Evolution of NA genes of human seasonal H1N1 influenza viruses.
Representative strains of seasonal human H1N1 influenza viruses from 1999-2009 were
chosen for construction of the tree. Seasonal H1N1 virus vaccine strains among the years
are filled by green color, and viruses reported to carry the H275Y NA mutation are filled
by red color. The phylogenetic analysis was based on alignment of coding sequences of
the N1 NA gene. The tree was constructed by using the neighbor-joining method (Kimura
two-parameter) with 1000 bootstrap replicates in the Mega4 program. Only bootstrap
values > 50 are shown. The bar represents 0.002 nucleotide substitutions per site.
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Table 3-1. Comparison of the amino acid consensus sequences of NA genes of
human seasonal H1N1 viruses of different lineages.
H1N1 virus
lineage

NA consensus amino acid residueb
NA genotype
(275 position)a 275 45 78 214 222 234 249 287 329 344 354

BR/59/07-like

wild-type

H

N

W

G

Q

M

K

I

E

N

D

H275Y mutant

Y

-

-

-

-

-

-

-

-

-

G

wild-type

H

H

K

E

R

V

G

T

K

D

G

H275Y mutant

Y

-

-

-

-

-

-

-

-

-

-

NC/20/99-like

a

Indicate the amino acid residue at the 275 position of NA protein.
In the table, the symbol “-” indicates the amino acid residue in the mutant viruses is the
same as the residue in the wild-type virus in the group.
b
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Figure 3-2. The structure of NA monomer (N1 subtype) showing the 275 position
and the 10 positions at which the amino acid substitutions differentiate the NAs of
NC99-like and BR07-like.
Surface-filling model of the neuraminidase protein of A/California/04/09 virus (PDB
3NSS) shows the location of the 8 positions of amino acid residues listed in the Table 31. Position 45 and 78 are located in stalk region of NA molecular, which is no included in
this protein structure. Both the top view and side view of the NA globular head were
showed for the same 8 positions. The respective residues at the 10 positions are labeled in
green and residue 275 is labeled in red which confers resistance to oseltamivir by the H to
T mutation. The structure view was generated by PyMOL software.

36

Table 3-2. Agreement of the NA genes of the H1N1 viruses with the respective NA
censuses sequences of human H1N1 viruses of different lineages at the 10 amino acid
positions plus the 275 position.
H1N1 virus
lineages and strains
(genotype at NA 275
position)a

NA amino acid residueb
275 45

78 214 222 234 249 287 329 344 354

Seasonal BR07-like
wild-type consensus

H

N

W

G

Q

M

K

I

E

N

D

BR/59/07 (wt)

-

-

-

-

-

-

-

-

-

-

-

CA/27/07 (wt)

-

-

-

-

-

-

-

-

-

-

-

H275Y variant consensus

Y

N

W

G

Q

M

K

I

E

N

G

HW/28/06 (H275Y)

-

-

-

-

-

-

-

-

-

-

D

NY/3467/09 (H275Y)

-

-

-

-

-

-

-

-

-

D

-

NY/1692/09 (H275Y)

-

-

-

-

-

-

-

-

-

-

-

NJ/15/07 (H275Y)

-

-

-

-

-

-

-

-

-

-

-

wild-type consensus

H

H

K

E

R

V

G

T

K

D

G

MEM/13/06 (wt)

-

-

-

-

-

-

-

-

-

-

-

GA/17/06 (wt)

-

-

-

-

-

-

-

-

-

-

-

MI/03/02 (wt)

-

-

-

-

Q

-

-

-

-

N

-

H275Y variant consensus

Y

H

K

E

R

V

G

T

K

D

G

GA/20/06 (H275Y)

-

-

-

-

-

-

-

-

-

-

-

MI/03/02 (H275Y)

-

-

-

-

Q

-

-

-

-

N

-

TX/30/07 (H275Y)

-

-

-

-

-

-

-

-

-

-

-

wild-type consensus

H

Q

Q

D

N

V

G

E

N

N

G

DM/524/09 (wt)

-

-

-

-

-

-

-

-

-

-

-

H275Y variant consensus

Y

Q

Q

D

N

V

G

E

N

N

G

DM/528/09 (H275Y)

-

-

-

-

-

-

-

-

-

-

-

Seasonal NC99-like

2009 pandemic H1N1
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Table 3-2. (Continued).
a

Indicates the amino acid residue at the 275 position of NA protein.
In the table, the “-” symbol indicates the amino acid residue in the mutant viruses as
same as the residue in the wild-type virus in the group.
b
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Transmissibility of Different Seasonal H1N1 Viruses in Ferrets
Transmissibility of wild-type and H275Y mutant BR07-like viruses in ferrets.
Transmissibility is considered as one of the most important clinical relevant properties of
influenza viruses, so we firstly assessed the transmissibility of the H1N1 viruses in a
ferret model. Four strains of BR07-like viruses were studied. The BR/59/07 virus is a
representative wild-type virus for this lineage, which is shown as the immediate ancestor
for the majority of H275Y mutant viruses that emerged between 2007~2009 (Fig 3-1).
The other three viruses share the same lineage as the BR/59/07 virus but harbor the NA
H275Y resistance marker and carry different NA molecular features: the NA gene of
NY/1692/09 virus is fully in agreement with the BR07-like consensus residues at the ten
positions, but the NA genes of HW/28/07 and NY/3467/09 virus differ in their consensus
residues at the 354 and 344 position respectively (Table 3-2).
We assessed the transmissibility of the four viruses in ferrets by both
direct-contact route and respiratory-droplet route. In this model for each virus group, 3
ferrets were intra-nasally inoculated with the same infectivity amount of the virus (donor
ferrets), then one naïve ferret was housed with each donor ferret in the same cage
(direct-contact route) at day 1 post-inoculation (p.i.), and another naïve ferret was placed
in an adjacent cage separated from the donor’s cage by two layers of perforated divider
(respiratory-droplet route) at the same time. Transmission of the viruses was assessed by
detection of infection in recipient ferrets (nasal wash titers, clinical signs, and
sero-conversion).
As regards to the donor ferrets, in each of the four virus groups, the intranasal
inoculation of the viruses resulted in successful infection in all donor ferrets (3/3) by
nasal wash titers and sero-conversion (Fig 3-3A, Table 3-3). The donor ferrets shed virus
productively with comparable peak virus titers and shedding duration among all 4 virus
groups. The donor virus shedding at day1 post infection (p.i) were further analyzed,
because day1 p.i was the time when the recipient ferrets were housed with the donors,
and the level of the donor shedding might indicate the level of environmental virus
exposure to the recipient ferrets at the time. Among all 4 virus groups, at day1 p.i only
donor ferrets in the NY/3467/09 virus group had slightly lower shedding (1.5
log10TCID50 lower) than the wild-type virus group, and the other 2 virus groups had
shedding titers comparable to the wild-type virus group (Fig 3-3A, Table 3-3).
Regarding to the direct-contact recipient ferrets, in each of the four virus groups,
all the co-caged recipient ferrets (3/3) acquired infection from their donor ferrets through
direct-contact transmission route, as shown by productive virus shedding over time and
confirmed by sero-conversion in the each ferret (Fig 3-3A, Table 3-3). But the efficiency
of acquisition of infection at day 1 post contact (p.c) was not entirely the same among the
different groups (Fig 3-3B, Table 3-3). In the wild-type BR/59/07 virus group all 3/3
ferrets acquired infection at day 1 p.c with high virus titers. In the HW/28/07 virus group,
only 2/3 ferrets acquired infection at day 1 p.c with one ferret of lower titer than the
wild-type group (~2 log10TCID50 lower). In the NY/3467/09 virus group, 3/3 ferrets
acquired infection at day 1 p.c with one ferret of lower titer than the wild-type group (~2
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Figure 3-3. Transmissibility of the seasonal H1N1 influenza viruses of two lineages
in ferrets.
(A) The virus titer in the nasal wash samples from each donor (black), direct-contact
(DC) recipient (blue), and respiratory-droplet (RD) recipient ferret (red) over the sample
collection time of 2 weeks. Each graph represents each different virus. The donor ferret
was housed with recipient ferrets at day1 p.i. (B) The virus titers at day 1 p.i in nasal
wash samples of the DC ferrets in different virus groups. Each dot represents individual
donor ferret in the virus group. (C) The virus titers in the nasal wash samples of first
detection of virus in the RD ferrets in different virus group. The day p.i of first detection
of virus in each group is indicated. * p<0.05 by t test when compared with MEM13
group.
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Table 3-3. Detection of virus replication and sero-conversion in ferrets during transmission of the H1N1 influenza
viruses.
Inoculated donors
H1N1 viruses
(NA genotype)a

Virus
sheddingb

Direct-contact recipients

Respiratory-droplet recipients

Duration
Duration
Duration
Serum HI
Serum HI
Serum HI
Virus
Virus
of
of
of
titerd
titerd
titerd
sheddingb
sheddingb
c
c
c
shedding
shedding
shedding

BR/59/07-like
BR/59/07 (wt)
HW/28/06 (H275Y)
NY/3467/09 (H275Y)
NY/1692/09 (H275Y)

3/3
(6.3/7.1)
3/3
(6.3/7.6)
3/3
(5.3/8.0)
3/3
(7.0/7.2)

6
2560, 1280,
3/3
7
(6,6,6)
1280
(3.0/6.9 ) (7,7,7)
6
2560, 2560,
3/3
6.3
(6,6,6)
1280
(1.8/7.2) (5,7,7 )
6
640, 640,
3/3
7
(6,6,6)
1280
(2.9/7.1) (7,7,7)
6
2560, 1280,
3/3
5.7
(6,6,6)
2560
(4.6/6.3) (5, 5, 7)

2560, 2560,
1280
2560, 2560,
2560
1280, 2560,
1280
1280, 2560,
1280

2/3
(6.0)
2/3
(6.25)
2/3
(6.1)
2/3
(5.9)

5
(5, 5)
5
(5, 5)
6
(7, 5)
5
(5, 5)

320, 1280,
<10
1280,
2560, <10
640, 640,
<10
2560,
2560, <10

3/3
(5.8/7.1)
3/3
(5.9/7.1)

6
2560, 2560,
(6,6,6)
2560
6
2560, 1280,
(6,6,6)
2560

5.7
2560, 640,
(5, 5, 7)
2560
7
2560, 1280,
(7, 7,7)
2560

2/3
(6.75)
2/3
(6.75)

6
(5, 7)
7
(7, 7)

2560,
1280, <10
1280,
1280, <10

3/3
(6.6/8.0)
3/3
(5.1*/6.9)
3/3
(3.5*/6.8)

6
2560, 2560,
3/3
7
2560, 2560,
(6,6,6)
2560
(3.7/7.4) (7, 7, 7)
2560
6
640, 1280,
3/3
6.3
640, 1280,
*
(6,6,6)
1280
(0.3 /6.7) (7, 5, 7)
1280
6
640, 1280,
3/3
7
640, 640
(6,6,6)
1280
(0.7*/6.2) (9,5,7)
1280

2/3
(6.1)
1/3
(6.3)
1/3
(7.0)

5
(5, 5)
3
(3)
5
(5)

1280,
1280, <10
320, <10,
<10
320, <10,
<10

rgBR/59/07 viruses
rgBR/59/07-NAH275Y
rgBR/59/07-NAH275Y+D354G

3/3
(1.2/7.1)
3/3
(2.9/7.2)

NC/20/99-like
MEM/13/06 (wt)
MI/03/02 (H275Y)
GA/20/06 (H275Y)
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Table 3-3. (Continued).
a

Indicates the amino acid residue genotype at the 275 position of NA protein either as wt (wild-type H275) or H275Y
mutation.
b
Number of virus-shedding animals/total number. Numbers in parentheses indicate mean virus titer at day1 p.i / mean peak
virus titer in nasal wash samples (log10TCID50/ml, n=3).
c
The number of the days from the first day of detection of virus titer till the last day of detection of virus titer. Numbers in
parentheses indicate days for each individual ferret in the group.
d
Hemagglutination inhibition (HI) antibody titers to homologous virus in ferret serum on day 21 p.i. Numbers indicate the HI
titer of each individual ferret in the group.
* Compared with the value in MEM/13/06 virus group, p<0.05, t test.
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log10TCID50); while in the NY/1692/09 virus group, 3/3 ferrets acquired infection and all
had higher titers than the wild-type group (~1.5 log10TCID50 higher). Nevertheless, in
spite of the differences in the acquisition of infection at day 1 p.c, all the direct-contact
ferrets reached comparable levels of peak virus shedding among the different groups. The
results suggested that both the BR07-like wild-type and H275Y mutant viruses were
easily transmitted to recipient ferrets through direct-contact route, although the efficiency
of the transmission of the H275Y mutant viruses varied from slightly lower, higher, or
similar efficiency than that of the wild-type BR/59/07 virus group.
As for the respiratory-droplet recipient ferrets, in each of the four virus groups,
only 2/3 recipient ferrets acquired infection from donor ferrets through
respiratory-droplet transmission, as shown by productive virus shedding in the nasal
washes and also confirmed by sero-conversion (Fig 3-3A, Table 3-3). 1/3 ferrets in each
group did not acquire infection over the observation time, as indicated by lack of
detection of virus shedding and sero-conversion. In general, compared with the
direct-contact transmission, the respiratory-droplet transmission not only had relatively
lower efficiency, but also had a greater lag time, varying from a delay of 2~6 days as
indicated by the first day of detection of virus shedding. Furthermore, the dynamics of
respiratory-droplet transmission into 2/3 ferrets was not entirely the same among the four
virus groups (Fig 3-3C). The two ferrets acquired infection at day 3, and 7 p.c
respectively in the wild-type BR/59/07 virus group as indicated by the first day of virus
detection; day 3 and 5 p.c respectively in the HW/28/07 virus group and day 3 and 5 p.c
respectively in the NY/3467/09 virus group, suggesting similar dynamics of transmission
of these three viruses to that of the wild-type virus. In the NY/1692/09 virus group, both
ferrets acquired infection at day 3 p.c, suggesting slightly faster transmission of this virus
than that of the wild-type virus. Overall, the results together suggest that both the
wild-type and H275Y mutant BR07-like viruses were able to be transmitted to recipient
ferrets through respiratory-droplet route, but with lower efficiency and a greater lag time
than direct contact-route; the H275Y mutant viruses were transmitted through
respiratory-droplet route at similar efficiency or even slightly faster dynamics than the
wild-type virus.
Regarding clinical signs, all the infected ferrets (by inoculation or transmission)
were observed with slight body weight loss (less than 5% of original body weight),
spontaneous sneezing, fluctuated body temperature, but no obvious fever during the time
of infection (data not shown). Among ferrets of the four virus groups there was no
significant difference observed in these clinical signs, suggesting that both wild-type and
H275Y mutant of BR07-like viruses caused a similar course of the disease with similar
severity of the disease.
In summary, these results suggested that compared to the wild-type BR07-like
virus, the BR07-like H275Y mutant viruses were transmitted among ferrets by both
direct-contact and respiratory-droplet routes at similar efficiency, with subtle variations
in dynamics depending on the viruses; the H275Y mutant viruses also caused a similar
course of disease with similar severity in donor and recipient ferrets as the wild-type
virus.
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Transmissibility of reverse-genetics BR/59/07 viruses carrying H275Y NA
mutation or/and D354G mutation. Reverse-genetics influenza viruses contain
homogeneous genetic backgrounds with specified mutations on segments, thus allow
precise evaluation the impact of the mutations on the virus. We then assessed the impact
of the H275Y mutation on the transmissibility of BR/59/07 virus by using
reverse-genetics BR/59/07 (rgBR/59/07) viruses carrying different mutations. The two
viruses were generated on the entire genetic background of the BR/59/07 virus. The first
virus rgBR/59/07-NAH275Y differs only at the NA H275Y mutation from the wild-type
BR/59/07 virus, which is similar to the NA genotype of HW/28/07 virus with regards to
the NA consensus residues (Table 3-2). The second virus rgBR/59/07-NAH275Y+D354G had
one more mutation D354G in addition to H275Y, which is similar to the NA genotype of
NY/1692/09 virus with regards to the NA consensus residues (Table 3-2). The
reverse-genetics viruses did not have differences in other genes, which was very likely in
those H1N1 virus isolates.
In both H275Y mutant virus groups, all the inoculated donor ferrets shed virus
productively, with day 1 p.i virus titers, peak virus titer and duration of virus shedding
comparable to those in the wild-type BR/59/07 virus group, suggesting no difference in
the virus replication in ferret upper respiratory tract among these two viruses and the
wild-type virus (Fig 3-3A, Table 3-3).
With regards to direct-contact transmission, all recipient ferrets (3/3) in each
group acquired infection from their donor ferrets, as indicated by productive virus
shedding and sero-conversion (Fig 3-3A, Table 3-3), but the efficiency of acquisition of
infection at day 1 p.c was distinct between the two groups (Fig 3-3B). In the
rgBR/59/07-NAH275Y virus group, only 2/3 ferrets acquired infection at the time, with one
ferret of lower virus titer than the wild-type virus group (~2 log10TCID50 lower) while in
the rgBR/59/07-NAH275Y+D354G virus group, 3/3 ferrets acquired infection with titers
approximate to those in the wild-type virus group. In spite of the shedding difference at
day1 p.c, all the receipt ferrets reached comparable peak virus shedding. The results
suggested that the H275Y mutation alone in the BR/59/07 virus minimally altered the
efficiency of direct-contact transmission and only caused a slight delay at early
transmission/infection stages, but the H275Y and D354G mutation together might negate
such a delay and restore the same transmission efficiency as that of the wild-type
BR/59/07 virus.
As for respiratory-droplet transmission, only 2/3 ferrets in each virus group
acquired infection. The efficiency of the transmission was the same as the wild-type virus
group (Fig 3-3A, Table 3-3), but the dynamics of the transmission were slightly different
(Fig 3-3C). In the rgBR/59/07-NAH275Y virus group 2 ferrets acquired infection at day 3,
7 p.c respectively as indicated by first day of detection of virus shedding, which was the
same as those in wild-type BR/59/07 virus group, while in the rgBR/59/07-NAH275Y+D354G
virus group 2 ferrets acquired infection at day 3, 5 p.c respectively, which was slightly
faster than those in the wild-type or the H275Y mutation virus groups. The results show
that the H275Y NA mutation alone minimally affected the efficiency and dynamics of
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respiratory-droplet transmission of the BR/59/07 virus, and the D354G and H275Y
mutations together might slightly facilitate the transmission.
In summary, by using the reverse-genetic viruses, we showed that the H275Y
mutation alone hardly compromised the productive transmission of the BR/59/07 virus by
both direct-contact and respiratory-droplet routes, although the dynamics of the
transmission could be slightly altered. The D354G, a NA mutation of high frequency
(>95%) in H275Y mutant viruses, together with H275Y mutation might slightly facilitate
the virus transmission by both routes. Thus, the D354G mutation was somewhat
beneficial for overall transmission of rgBR/59/07 virus with the H275Y mutation alone.
As for clinical signs in the infected ferrets, there was no apparent difference observed
among the three virus groups. Notably, the efficiency and dynamics of transmission of
the rgBR/59/07-NAH275Y and rgBR/59/07-NAH275Y+D354G viruses were in line with those
of HW/28/08 and NY/1692/09 viruses respectively, which are of similar NA genotype
with regards to the consensus residues.
Transmissibility of wild-type and H275Y mutant NC99-like viruses in ferrets.
In comparison to the transmissibility of the BR07-like H1N1 viruses, we then studied the
transmissibility of three strains of NC-99-like viruses in the ferret model. MEM/13/06
virus is a representative wild-type virus for this lineage (Fig 3-1), which shares the same
lineage as the NC/20/99 virus. Two other viruses also fall into the NC/99 lineage (Fig
3-1), but harbor the H275Y NA mutation and carry different NA molecular features. The
NA gene of GA/20/06 virus is fully in agreement with the consensus residues at the ten
positions, while the NA gene of MI/03/02 virus differs at the 222 and 344 positions from
the NC99-like consensus residues (Table 3-2).
We evaluated the transmissibility of these viruses among ferrets by both
direct-contact and respiratory-droplet route. The experimental settings and protocol were
the same as described above for the BR/59/07-like viruses.
As for the donor ferrets, in each of the three virus groups, the intranasal
inoculation of viruses resulted in successful infection in all donor ferrets (3/3), as
indicated by productive virus shedding and sero-conversion (Fig 3-3A, Table 3-3). The
donor ferrets had comparable peak virus titers and virus shedding duration among all
three virus groups, but both of the H275Y mutant GA/20/06 and MI/03/02 virus groups
had significantly lower average virus titers than the wild-type virus group at day 1 p.i
(~ 3 and 1.5 log10TCID50 lower respectively, p<0.05). The results suggest that the two
NC/99-like H275Y mutant viruses had significantly delayed virus replication in ferret
upper respiratory tract compared with the wild-type virus.
With regards to direct-contact transmission in each of the three virus groups, all
recipient ferrets (3/3) acquired infection from their donor ferrets as indicated by virus
shedding and sero-conversion (Fig 3-3A, Table 3-3), but the efficiency of acquisition of
infection at day 1 p.c. was distinct among groups (Fig 3-3B). In the wild-type
MEM/13/06 virus group, 3/3 ferrets acquired infection at day 1 p.c with high titers, but in
both the GA/20/06 virus and MI/03/02 virus groups only 2/3 and 1/3 ferrets respectively
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acquired infection at the time, with significantly lower virus titers than those in the
wild-type virus group (~ 3 log10TCID50 lower, p<0.05). The results suggested that both
NC/99-like H275Y mutant viruses had significantly delayed direct-contact transmission
than the wild-type virus.
Regarding to respiratory-droplet transmission, in the wild-type MEM/13/06 virus
group, 2/3 recipient ferrets acquired infection from donor ferrets at day 3, 5 p.c
respectively as indicated by the first day of virus detection in nasal washes (Fig 3-3A,
Table 3-3). However, in both GA/20/06 virus and MEM/13/06 virus groups only 1/3
recipient ferrets acquired infection and the other two recipient ferrets were not able to
acquire infection during the whole observation time, as indicated by lack of detection of
virus shedding and sero-conversion. Moreover, in the two H275Y mutant virus groups,
the one infected recipient ferret acquired infection at day 7, 9 p.c. respectively (Fig 3-3C).
This was considerably more delayed than the day 3 or 5 p.c in the wild-type virus group.
The results suggested that the NC99-like H275Y mutant viruses were transmitted with
considerably less efficiency than the wild-type virus through respiratory droplet route.
In summary, the results suggested that compared to the wild-type virus, the
replication of NC99-like H275Y mutant viruses by inoculation in the ferret upper
respiratory tract was significantly delayed at early stage, and transmission of the
NC99-like H275Y mutant viruses in ferrets was considerably less efficient and slower
than the wild-type virus by both direct-contact and respiratory-droplet routes.
Notably, when the NC99-like and BR07-like groups are compared, the
transmissibility of the NC99-like wild-type virus was indistinguishable to its counterpart
BR07-like wild-type virus, while the transmissibility of the NC99-like H275Y mutant
viruses was remarkably reduced in terms of transmission efficiency and dynamics by
both routes when compared with their counterpart BR07-like H275Y mutant virus.
Growth Capability of Different Seasonal H1N1 Viruses in Cell Culture
Virus growth capability is another important overall virus characteristic of
influenza viruses, so we evaluated single-cycle growth of the BR07-like and NC99-like
H1N1 viruses in NHBE cells. NHBE cells grow and differentiate on air-liquid interfaces
and support influenza virus growth without the addition of TPCK trypsin, making them
the best representation of epithelial cell lining in the respiratory tract. All the four
BR07-like viruses used in the transmission study were evaluated for their growth
capabilities. Two pairs of NC99-like viruses, which had NA genes only differing at the
275 position within each pair, were evaluated for virus growth capabilities. In NHBE
cells, for the BR07-like virus group (Fig 3-4), all three H275Y mutant viruses eventually
grew to peak titers comparable to the wild-type virus at 12 hours p.i, although one virus
HW/28/07 had delayed growth. In contrast, for the two pairs of NC99-like viruses (Fig
3-4), both the H275Y mutant viruses only grow to titers significantly lower than their
counterpart wild-type viruses by 12 hours p.i (~2 log10TCID50 lower, p<0.05).
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Figure 3-4. Growth capability of different H1N1 viruses in NHBE cells.
Single-cycle growth curves of different H1N1 viruses in MDCK cells were obtained by
using an MOI of ~2 PFU/cell, respectively. Wild-type viruses are drawn in black solid
lines and H275Y mutant viruses are drew in grey dashed lines. Virus in the supernatant
was titrated in MDCK cells and expressed as log10TCID50/ml at the indicated time
post-infection (p.i). Each point represents the mean value ± SD from three replicates.
* p<0.05 by t test, compared with the respective wild-type virus at the same time point.
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We also examined the plaque morphology by these H1N1 viruses in MDCK cells.
Most viruses showed heterogeneous plaque sizes, and overall, the BR07-like viruses
generated bigger plaques than the NC99-like viruses regardless of the H275Y mutation
(data not shown), which is in agreement with previous reports on plaque morphology of
H1N1 viruses (61).
Taken together, the results showed that in the cells, the growth capability of the
BR07-like H275Y mutant viruses was approximate to their counterpart wild-type virus
although with variations. In contrast, the growth capability of the NC99-like H275Y
mutant viruses was considerably attenuated when compared with their counterpart
wild-type viruses.
NA Enzyme Activity, Protein Expression and Enzyme Kinetics of Different Seasonal
H1N1 Viruses in vitro
Generation and characterization of epitope-tagged recombinant NA proteins.
In order to understand if the difference in transmissibility and infectivity of the
characterized H1N1 viruses was associated to the NA enzyme function in the viruses, we
assessed the NA enzyme activities of the BR07-like and NC99-like H1N1 viruses in vitro
using a fluorescence-based substrate. When the whole virus particles standardized by the
same infectivity were used for the assay, the results showed no significant difference of
NA activity among different lineages, and failed to give any discernable trend among
different groups (data not shown), which is in agreement with a previous report that no
difference was found among the NA activities of wild-type and H275Y mutant H1N1
viruses (68). We speculated that the reason that such results were not informative could
root in two major flaws about using whole virus particles for the assay: 1) virus particle
quantitation can never be accurate enough and the errors masked the potential difference,
as replication defective particles cannot be measured in infectivity assays and the
infectivity assays by themselves are inaccurate; 2) the amount of virus surface NA
protein was not counted into the analysis even if the virus particles were standardized, as
different amount of NA proteins can be incorporated into the virus particle driven by
different M proteins or different expression levels of the NA protein themselves. In order
to overcome both potential flaws, we sought to measure enzyme activity of the NA
proteins rather than the whole virus particles, which need antibodies to recognize the NA
proteins. Due to the lack of one kind of anti-NA antibodies that can recognize all the NA
variants with the same binding affinity, we generated the recombinant NA proteins with
the same epitope tag, which allow quantitation of different NA protein variants for the
following activity assay. We chose the HA epitope tag for the recombinant NA protein as
it was reported previously (67).
We firstly assessed if the addition of the epitope tag to either NA protein terminus
could affect the protein expression in cells (Fig 3-5). We generated the un-tagged,
C-terminal tagged and N-terminal tagged recombinant proteins of the NA of BR59/07
virus and compared their expression levels (Fig 3-5A). First off, the expression levels of
either tagged proteins were in proportion to the amounts of the plasmids transfected into
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Figure 3-5. Generation and characterization of epitope-tagged recombinant NA
protein of BR/59/07 virus.
(A) The detection of different tagged recombinant BR/59/07-NA protein in BHK cells by
western blot. The amounts of respective plasmids for transfection are labeled
accordingly. The upper panel is the detection by anti-HA tag antibodies, and the lower is
by anti-Actin antibodies. (B) The NA enzyme activity of the different tagged
recombinant proteins in cells expressed by 0.5 μg respective plasmids for transfection.
The data were normalized to the untagged protein (100%). * p< 0.05 by t test compared
the untagged NA group. (C) The enzyme activity exhibited by untagged or C-terminal
tagged proteins expressed by 0.5 and 1.5 μg respective plasmids. (D) The enzyme
kinetics (Vmax at left Y axis and Km at right Y axis) exhibited by untagged or
C-terminal tagged proteins expressed by 0.5 and 1.5 μg respective plasmids.
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the cells. Secondly, the expression level of the N-terminal tagged NA protein was
constantly much lower than that of the C-terminal tagged protein based on the density of
the protein bands. The expression levels of the C-terminal tagged and untagged NA
protein cannot be directly compared by protein detection, but NA enzyme activity
measurement showed that the two proteins exhibited approximately equivalent activities
(Fig 3-5B), suggesting equivalent protein expression levels between the two proteins. In
contrast, the N-terminal tagged protein retained a significantly lower amount of activity
than the untagged and the C-terminal tagged proteins (p<0.05) (Fig 3-5B), which is in
agreement with the protein detection results (Fig 3-5A). The comparison suggested that
the C-terminal HA epitope tag did not alter the level of the NA protein expression and
activity, so the C-terminal epitope tag was chosen for generation of all recombinant NA
proteins.
Next, we examined the surface accumulation of the C-terminal tagged NA protein
of BR/59/07 virus. During the life cycle of an influenza virus, the expressed NA proteins
are reportedly transported to the cell surface to be incorporated into nascent virus
particles. In order to make the results of NA protein expression mostly relevant to the
levels of NA proteins incorporated into virus particles, we assessed the cell surface
accumulation of the recombinant NA proteins. First of all, in the protein blot images, a
relatively faint band was consistently found to accompany the major protein band (in
either C- or N-terminal tagged protein images), and the density of the second band was
always in proportion with its corresponding major band (Fig 3-5A). Considering their
slightly higher molecular weight, presumably, the second protein bands could be the
glycosylated NA proteins being transported to the cell surface. Secondly, we examined
the cell surface accumulation of the NA proteins by flowcytometry (Fig 3-6). The results
showed the accumulation of the C-terminal tagged NA proteins at the cell surface, and
the accumulation intensity was in proportion to the amounts of the plasmids transfected
into the cells.
Furthermore, we characterized the function of the C-terminal tagged NA protein
of BR/59/07 virus in comparison to the untagged NA protein. The enzyme activities
exhibited by both proteins were proportionate with their protein expression levels (Fig
3-5C), which were proportionate to the amounts of the plasmids transfected into the cells
(Fig 3-5C). The enzyme properties Km and Vmax were determined for both the
recombinant proteins (Fig 3-5D). Km is the dissociation constant for enzyme binding to
the substrate, which is intrinsic to the enzyme and independent of the about of protein
presented in the reaction; Vmax reflects catalytic capability of the enzyme and is
dependent on both the enzyme turnover rate (Kcat) and the amount of enzyme present in
the reaction. The results showed that both the C-terminal tagged, untagged NA proteins
(Fig 3-5D), and whole virus particles exhibited comparable Km values (data not shown),
despite different amounts of the proteins or virus particles used for the assays. Both the
recombinant NA proteins exhibited comparable Vmax values, which were proportionate
to their expression amounts (Fig 3-5A). The results suggested that the C-terminal tagged
NA protein retained the enzyme properties indistinguishable to the untagged NA protein,
and could represent the original NA protein properly.
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Figure 3-6. The cell surface protein accumulation of C-terminal tagged BR07-NA
protein.
The detection of the surface accumulation of the BR07-NA protein by flowcytometry.
The different lines indicate the protein accumulation expressed by different amount of
plasmids for transfection, which was, from left to right, 0, 0.1, 0.5, 1.5 μg of the plasmids
into cells.
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Enzyme activities of recombinant NA proteins of H1N1 viruses in vitro. Next,
we generated and compared the C-terminal tagged recombinant NA proteins of different
H1N1 viruses. All of the data were normalized to the activity of wild-type NA of the
BR/59/07 virus (BR/59/07-NA) (Fig 3-7A). In the BR07-like group, the 5 different
H275Y mutant NA proteins exhibited enzyme activities approximate to the BR/59-NA
protein with small variations (Fig 3-7A); especially, the BR/59/07-NAH275Y protein
exhibited a marginal loss (~20%, data not shown separately) of enzyme activity
compared with the BR/59/07-NA protein, which only differs from each other at the
H275Y mutation. However, in the NC99-like group, not only the 3 different wild-type
NA proteins exhibited much lower activity than their wild-type counterpart BR/59/07-NA
protein in the BR07-like group, but also the 3 different H275Y mutant NA proteins
exhibited drastic losses of the activity (~50%) compared with the corresponding 3
wild-type NA proteins (Fig 3-7A). Noted, the highest enzyme activities in either the
wild-type or H275Y mutant NA proteins in the NC99-like group were from the MI/03/02
viruses, which differ from the NC99-like consensus residues at the 222 and 344 positions
(Table 3-2).
Taken together, the results showed that the enzyme activities of BR07-like
H275Y mutant NAs were minimally impaired compared to that of BR07-like wild-type
NA, but the enzyme activities of the NC99-like H275Y NAs were severely diminished
compared to those of their corresponding wild-type NAs, which were inherently-low by
themselves. The results suggested that the enzyme activities of the wild-type NAs of the
two different lineages are inherently distinct in the first place, and the H275Y mutation
had differential effects on enzyme activity of the NAs of the two different lineages.
Expression levels of recombinant NA proteins of H1N1 viruses in cells.
Reduced enzyme activity of the NA proteins can directly result from a reduced
expression level of the proteins in cells. We next examined the expression levels of the
recombinant NA proteins of the H1N1 viruses (Fig 3-7B). The total expression levels of
the NA proteins in cells were examined by western blot. In the BR07-like group, the
respective expression of 5 different H275Y NA proteins were similar to that of the
wild-type BR/59/07-NA protein although with slight variations based on the density of
the protein bands (Fig 3-7B). Especially, the BR/59/07-NAH275Y protein showed minimal
change of expression level compared with the BR/59/07-NA protein. However, in the
NC99-like group each of the 3 H275Y mutant NA proteins showed greatly reduced
expression levels compared with their counterpart wild-type NA proteins (Fig 3-7B).
Additionally, when the NC99-like and BR07-like groups are compared, each of the 3
NC99-like wild-type NA proteins showed naturally lower protein expression levels than
the wild-type BR/59/07-NA respectively, and the 3 NC99-like H275Y mutant NA
proteins showed greatly diminished protein accumulation compared with the BR07-like
NA proteins.
We further examined the cell surface accumulation of 4 pairs of NA proteins of
different viruses (Fig 3-7C). In each pair, the two NA proteins only differ from each other
at the 275 position. In the BR07-NA group, the protein accumulation profiles of the
H275Y mutant NA proteins were overlapped together with that of the wild-type NA
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Figure 3-7. The NA enzyme activities, protein expression levels and enzyme Km
values of different seasonal H1N1 influenza viruses.
(A) The enzyme activities of C-terminal tagged recombinant NA proteins of different
H1N1 viruses. The data were normalized to the BR/59/07-NA. Each dot represents the
mean value of three determinations of each different NA protein. The NA protein
designations are entirely the same as in B panel. (B) The detection of the recombinant
NA proteins of each virus by western blot. The upper panel is the detection by anti-HA
tag antibodies, and the lower is by anti-Actin antibodies. (C) The detection of the cell
surface accumulation of the 4 pairs of recombinant NA proteins by flowcytometry. Each
panel is for each pair of NA proteins which only differs at 275 position in the pair (upper
right BR/59/07 virus, upper left GA/17/06 and GA/20/06 viruses, lower right
MEM/13/06 virus, lower left MI/03/02 viruses) .In each panel, the black line and the red
line indicate the wild-type and the H275Y mutant NA protein respectively and two lines
should be compared within each panel. (D) The NA enzyme Km value of different H1N1
viruses. Each dot represents the mean value of three determinations of each virus,
although the data were not shown separately.
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protein (Fig 3-7C), suggesting that the surface accumulations of the two proteins were
indistinguishable. However, in other three NC99-like NA groups, the profile of each
H275Y mutant NA protein greatly shifted to the left compared to its counterpart
wild-type NA protein in the pair (Fig 3-7C), suggesting their greatly diminished cell
surface accumulation. The results of cell surface NA accumulation and were consistent
with the results of total NA protein expression in cells, suggesting that the lower cell
surface NA accumulation could directly result from its lower protein expression in the
cells.
Taken together, the results showed that both the total protein expression and the
cell surface protein accumulation of the BR07-like H275Y mutant NAs were hardly
altered compared with those of the BR07-like wild-type NA. However, both the total and
surface protein accumulation of the NC99-like H275Y mutant NAs were greatly
diminished compared with those of their counterpart NC99-like wild-type NAs. The
results suggested that the protein expression level of the wild-type NAs of the two
different lineages are naturally distinct in the first place, and the H275Y mutation had
differential effects on the level of protein expression of the NAs of the two different
lineages.
NA enzyme kinetics of the H1N1 viruses in vitro. Reduced enzyme activity of
NA proteins can also result from reduced functional capability of the NA enzymes. Two
enzyme kinetic parameters measure enzymatic functional capability: Km and Vmax. Km
is an estimate of the dissociation equilibrium of enzyme binding to the substrate, and the
reciprocal of Km approximates the enzyme affinity to substrate binding; Vmax reflects
the catalytic activity of the enzyme and is determined by the reactive amino acid residues
at enzyme active site and the amount of enzyme. Since none of the variant NA residues
between the H1N1 viruses are located at the active site and the NA protein expression
levels have been evaluated, only Km (the dissociation constant) was further determined
for evaluation of the NA enzyme affinity to substrate binding.
In each of the BR07-like and NC99-like groups, all the H275Y mutant viruses
exhibited higher average NA Km values than the wild-type viruses: ~50 μM vs ~ 20 μM
in the BR07-like group and ~ 200 μM vs 100 μM in the NC99-like group (Fig 3-7D),
indicating lower substrate binding affinity in these H275Y mutant NAs than those of their
counterpart wild-type NAs. However, when the BR07-like and NC99-like groups were
compared, the results showed the NA Km values of two groups were but at different
levels, which were ~100 μM vs 20 μM between the NC99-like and BR07-like wild-type
viruses, and were ~200μM vs 50 μM between the H275Y mutant viruses in two groups
(Fig 3-7D), suggesting inherently-low enzyme affinity in the NC99-like NAs. Noted, the
highest NA Km value in H275Y mutant viruses in the BR07-like group was from
NY/3467/09 virus, which differs from its consensus residues at the 344 position (Table
3-2). The lowest NA Km values in either wild-type or H275Y mutant viruses in the
NC99-like group were from the MI/03/02 viruses, which differ from their consensus
residues at two positions (Table 3-2).
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Taken together, the results showed that the BR07-like H275Y mutant viruses had
only slightly reduced NA enzyme affinities compared to their counterpart wild-type
viruses due to the inherently-high level of NA affinity in this lineage. However, the
NC99-like H275Y mutant viruses have greatly diminished NA affinities compared to
their counterpart wild-type viruses due to the inherently-low level of NA affinity in this
lineage. The results were consistent with but also further expanded previous reports
(63;69;70), suggesting that the enzyme affinity of the wild-type NAs of the two different
lineages were inherently distinct in the first place, and the H275Y mutation had
differential effects on the level of enzyme affinity of the NAs of two different lineages.
To summarize the in vitro characterization of the NAs of different H1N1 viruses,
between the BR07-like and NC99-like groups, with regards to the wild-type NAs,
BR07-like NAs had naturally higher enzyme activities than the NC99-like NAs, due to
the higher level of NA protein expression and NA enzyme affinity. Within the BR07-like
group, compared to the wild-type NA, the H275Y mutant NAs had minimally impaired
enzyme activities because of the minimally reduced naturally-high protein expression and
enzyme affinities. Within the NC99-like group, compared with the wild-type NAs, the
H275Y mutant NAs had greatly diminished enzyme activities, as a result of further
reduced naturally-low NA protein expression and enzyme affinities. The results
suggested that the H275Y mutation commonly had a negative effect on the NA protein
expression and enzyme affinity, but the degree of effects could be minimal as in
BR07-like NAs, or be drastic as in NC99-like NAs. In other words, the BR07-like NAs
had tolerance to the H275Y mutation, but the NC99-like NAs had no tolerance to it.
In summary of the in vivo and in vitro phenotype characterization of different
H1N1 viruses, in the BR07-like virus lineage, the wild-type NAs were naturally-high in
quantity (protein expression) and quality (enzyme affinity), so they could tolerate the
negative effects of the H275Y mutation on the protein expression and enzyme affinity
and the H275Y mutant NAs only had a marginal loss of NA activity; as a result, the
H275Y mutant viruses were minimally compromised in terms of virus infectivity and
transmissibility, and were allowed in the BR07-like lineage. However, in the NC99-like
virus lineage, the wild-type NAs were inherently-low in quantity and quality, so they
were not able to tolerate the deleterious effects of the H275Y mutation on the protein
expression and enzyme affinity and H275Y mutant NAs had a great loss of NA activity;
as a results, the H275Y mutant viruses were severely compromised in terms of virus
infectivity and transmissibility, thus they were extinct in the NC99-like lineage.
Effects of the Single Amino Acid Substitutions in BR07-NA Gene (from BR07-like to
NC99-like) on Protein Function and Expression
Effects of NA variants of different enzyme activities on plaque morphology of
the reverse-genetics viruses. Next, we sought to find the NA molecular basis for the
distinct quantity and quality of NA proteins of the BR07-like and NC99-like lineages. We
firstly chose two pairs of NA genes/proteins with one wild-type and another H275Y
mutant to represent each lineage for subsequent in vitro characterization. The NA gene of
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wild-type BR/59/07 virus (BR07-NA) and its H275Y variant acquired by mutagenesis at
the 275 position (BR07-NAH275Y) were chosen to represent the BR07-like lineage. The
NA genes of viruses GA/17/06 and GA/20/06 viruses (GA06-NA, GA06-NAH275Y) which
naturally only differ at H275Y mutation were chosen to represent the NC99-like lineage.
Since the two pairs of NAs (BR07 and GA06 pair) showed very contrasting levels
of NA activity in vitro (Fig 3-5A, 2-6A), we further tested if the different levels of NA
activity could affect the virus growth in terms of plaque size in MDCK cells. We
generated the reverse genetic viruses by using the 7 segments (except the NA segment)
from the BR/59/07 virus with the two pairs of NA genes respectively. Among the 4
reverse-genetics viruses, BR07-NA generated big clear plaques (1.8 mm), without
apparent reduction of the plaque size by the presence of H275Y mutation
(BR07-NAH275Y) (1.8 mm) (Fig 3-8A, B); in contrast, GA06-NA only generated
pinpoint-like small plaques (0.5 mm), and even smaller plaques with the presence of
H275Y mutation (GA06-NAH275Y) (0.3 mm) (Fig 3-8A, B). In these reverse-genetics
viruses, the virus absorption and replication by the same viral 7 proteins were totally the
same and only the release and spread of progeny virus by different NA proteins was
different, thus the plaque sizes can be associated with different function levels of the NA
variants during virus growth in the cells. The results suggested that the plaque sizes of the
reverse-genetics viruses, which only differed at the NA genes, were positively correlated
with the levels of their NA enzyme activities. In other words, the lower NA activity, the
smaller plaque size, and vice versa.
Effects of the single amino acid substitutions (from BR07-like to NC99-like)
in BR07-NA gene on plaque morphology of the reverse-genetics viruses. Based on the
results that the level of NA activity can determine the plaque size of the reverse-genetics
viruses, we took a “loss-of-activity” and “reduction-of-size” strategy to find the amino
acid residues in the BR07-NA protein which are responsible for its high enzyme activity.
We used the reduction of plaque size of reverse genetic viruses of NA variants as the first
criteria to probe potential activity-reducing amino acid in the BR59-NA. There are only
10 amino acid substitutions differentiating between BR07-like and NC99-like NAs
(Table 3-1). We substituted each of the 10 amino acid residues in the BR07-NA gene
with the corresponding NC99-like consensus residues respectively, as N45H+W78K,
G214R, Q222R, M234V, K249G, I287T, E329K, N344D, D354G (the 45 and 78
positions were placed together because they are the only two residues located in the stalk
region of NA), with the absence or the presence of the H275Y mutation respectively, then
we generated the reverse genetics viruses by using the 18 variants of the BR07-NA gene.
The plaque assay in MDCK cells showed that regardless of the presence of the H275Y
mutation, the majority of the substitutions did not cause an appreciable change in the
plaque size of the viruses (Fig 3-8C), and only 4 respective substitutions (Q222R,
M234V, E329K and N344D) resulted in significantly reduced plaque size in a different
manner (p<0.05) (Fig 3-8C, Fig 3-9). Specifically, the Q222R and E329K caused
drastically reduced plaque sizes of the viruses regardless of the H275Y mutation (0.7, 0.8
mm respectively and 0.6, 0.7 mm respectively with the presence of the H275Y). The
M234V or N344D alone caused a marginal change in the plaque sizes (1.5, 1.7 mm
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Figure 3-8. The plaque sizes of rgBR/59/07 viruses containing different NA gene
variants.
(A) The plaque sizes (left Y axis) of rgBR/59/07 viruses using two pairs of NA gene
variants (BR07 and GA06 pair), and the enzyme activities (right Y axis) of each pair of
proteins. The diameters of 10 randomly selected plaques were measured. Values are
mean plaque diameters (mm) ± SD * p<0.05 by t test between indicated groups. (B) The
plaque morphology of the rgBR/59/07 (rgBR/59) viruses using two pairs of NA variants.
(C) The plaque sizes of rgBR/59/07 viruses using 20 different NA variants of different
single amino acid residue substitution with the absence (wt-H275) or the presence
(H275Y) of the H275Y mutation. The mutations are indicated in each group.
*, ** p<0.05 by t test when compared with rgBR59-wt-H275 or rgBR59-wt-H275Y
respectively.
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Figure 3-9. The plaque morphologies of rgBR/59/07 viruses of single amino acid
residue substitutions in the NA gene.
The plaque morphology of rgBR/59/07 viruses using 10 different BR07-NA gene
variants of different single amino acid residue substitution with the absence (wt-H275) or
the presence (mut-H275Y) of the H275Y mutation. The mutation sites are indicated
above in each image.
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respectively), but caused a greater reduction of the plaque sizes at the presence of the
H275Y mutation (1.0, 0.9 mm respectively). The results suggested that the 4 amino acid
substitutions which caused notable change of the virus plaque sizes could potentially
cause decrease of the NA activity in the viruses. We chose these 4 NA amino acid
positions for further evaluations, but acknowledged that the other 6 substitutions might
also exert certain effects on the NA activity, but not big enough to cause a detectable
change in the virus plaque size. The NA position 354 exhibited unique amino acid
residue reversion (Table 3-1), so this position also was included along with other 4
positions for future analysis.
Effects of the single amino acid substitutions (from BR07-like to NC99-like)
in BR07-NA gene on protein function and expression. We identified 4 amino acid
substitutions in the BR07-NA gene causing reduction of the virus plaque sizes, so we
proceeded to evaluate if the four substitutions caused loss of activity in the NA proteins
and by which mechanism. We determined the enzyme activities of the 12 variant
BR07-NA proteins of the single amino acid substitutions (Fig 3-10A). First, the H275Y
mutation alone in the BR07-NA protein only caused a small decrease of the enzyme
activity; secondly, each of the substitutions (Q222R, M234V, E329K, N344D) in the
BR07-NA caused a significant decrease of the enzyme activity with a greater magnitude
at the presence of the H275Y mutation (p<0.5), which were correlated with the reduced
virus plaque sizes caused by these substitutions (Fig 3-8C). The D354G in the BR07-NA
increased the enzyme activity which was opposite to other 4 substitutions (Fig 3-10C),
although it did not cause a notable change in virus plaque size (Fig 3-8C).
We tested the effects of each of the 5 amino acid residue substitutions on the
protein expression and enzyme affinity of BR07-NA (Fig 3-10B). First off, The H275Y
mutation alone in the BR07-NA caused minimal change in the protein expression; two
substitutions (Q222R, M234V) in the BR07-NA severely ablated the level of protein
expression, even to a lower level with the presence of the H275Y mutation; the other 3
substitutions did not appear to affect the level of protein expression. Secondly, as regard
to the effects on the NA enzyme affinity (Fig 3-10C);, the H275Y mutation alone in
BR07-NA slightly increased the Km value three substitutions (Q222R, E329K, N344D)
in the BR07-NA significantly raised the enzyme Km values (P<0.05), to a bigger degree
with the presence of the H275Y mutation, while the D354G substitution in BR07-NA did
not show any apparent impact on the Km values. The results together suggest that the 4
substitutions in the BR07-NA reduced the NA activity by two different mechanisms, and
only the Q222R played both roles.
BR07-NA resulted in a slightly reduced unit activity, which can be associated
with its slightly reduced enzyme affinity. Furthermore, the Q222R substitution in the
BR07-NA led to a remarkably low unit activity with either the absence or presence of the
H275Y mutation, so its dual role in protein expression and enzyme affinity explained the
most drastic decrease of activity by this substitution. The M234V in the BR07-NA
retained a similar level of unit activity, suggesting this substitution only reduced the
protein expression, but not the enzyme affinity; both the E329K and N344D led to
reduced unit activities to a greater magnitude with the presence of the H275Y mutation.
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Figure 3-10. Effects of five different single amino acid substitutions in the BR07-NA
genes on NA enzyme activity, km value and protein expression.
(A) The enzyme activities of the variant BR07-NA proteins with 5 different single amino
acid substitutions with the absence or presence of the H275Y mutation respectively. Each
substitution is labeled below the graph. (B) The detection of the same variant BR07-NA
proteins of the 5 single amino acid substitutions by western blot. The upper panel is the
detection by anti-HA tag antibodies, and the lower is by anti-Actin antibodies. (C) The
NA enzyme Km value of the rgBR/59/07 viruses of BR07-NA variants of the 5 single
substitutions by enzyme kinetics assay. (D) The enzyme activity per unit of protein
(random unit of gray-scale of protein band) of the variant BR07-NA proteins of the 5
single substitutions. The data were calculated by using the enzyme activity of each NA
variant divided by the protein quantity (measured as the density of the protein bands), and
then the results were relative to the BR07-NA-wt. In all graphs, all values are the mean of
3 determinations ± SD. *, **< 0.05 by t test when compared to BR/59 or BR/59-H275Y
respectively.
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The D354G in the BR07-NA was the only substitution increasing the unit activity,
consistent with the increased enzyme activity above, but apparently not through the
mechanism of enzyme affinity.
In conclusion, by using a loss-of-activity strategy in the BR07-NA, we discovered
that in the genetic background of the BR07-like NAs, one group of molecular markers
(Q222 and M234 residues) functioned to keep the high level of NA protein expression,
and another group of molecular markers (Q222, K249 and N344 residues) served to
provide the high level of NA enzyme affinity to substrate binding. The two groups of
markers not only maintained the high quantity and high quality of the BR07-like NAs,
and more importantly, they also essentially counteracted the negative effects of the
H275Y mutation on the protein expression and enzyme affinity, thus conferring the
H275Y tolerance to the NA protein. In addition, the D354G substitution in the BR07-NA
somehow increased the enzyme activity even with the presence of the H275Y mutation,
by unidentified mechanism.
Effects of the Reciprocal Single Amino Acid Substitutions in GA06-NA Genes (from
NC99-like to BR07-like) on Protein Function and Expression
Now that we identified 4 amino acid residues (Q222, M234, K249, N344) in the
BR07-NA responsible for its high NA quantity and quality, we proceeded to tested if the
reciprocal amino acid substitutions (from NC99-like to BR07-like) at the 4 positions in
NC99-like NAs were able to restore the low quantity and quality of NC99-like NAs to
the high level of BR07-like NAs. We substituted each of the 4 amino acid residues in the
GA06-NA gene (NC99-like lineage) with the corresponding BR07-like consensus
residues respectively, as R222Q, V234M, E329K and D344N, with the absence or the
presence of the H275Y mutation. Then we generated the reverse-genetics viruses by
using the 8 variants of the GA06-NA genes and compared them with the GA06-NA and
BR07-NA derived viruses as described above. The GA06-NA naturally has G residue at
the 354 position, so the D354G reversion was not counted into the analysis. The impact
of each of the 4 substitutions in the GA06-NA gene on virus plaque size, enzyme activity,
protein expression and enzyme affinity were examined and compared.
As for the plaque size of the reverse-genetic viruses (Fig 3-11A, Fig 3-12), the
GA06-NA gene generated pinpoint-like plaques owning to its low activities (0.5 mm) as
showed above, and the H275Y mutation in the GA06-NA caused a further reduction of
the inherently small plaque size (0.3 mm). Each of the 4 substitutions in the GA06-NA
increased the virus plaque size respectively but to different magnitudes: the R222Q or
E329K alone significantly increased virus plaque size (1.3 and 2.0 mm respectively,
p<0.05) but to a slightly smaller degree with the presence of the H275Y mutation (1.1
and 1.8 mm respectively). The V234M or D344N alone in the BR07-NA did not greatly
change the virus plaque size (0.6 and 0.6 mm respectively), but with the presence of the
H275Y mutation, both substitutions effectively prevented the further plaque size
reduction by the H275Y mutation (0.6 and 0.5 mm respectively).
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Figure 3-11. Effects of four different single amino acid substitutions in the GA06NA genes on plaque size of reverse-genetics viruses, NA enzyme activity, NA Km
value and NA protein expression.
(A) The plaque sizes of the rgBR/59/07 viruses by using 10 variants of GA06-NA genes
with 4 different single amino acid substitutions at the absence or presence of the H275Y
mutation respectively. The enzyme activities (B) and protein detections (C) of the variant
GA06-NA proteins with the 4 single substitutions with the absence or presence of the
H275Y mutation respectively. (C) The upper panel is the detection by anti-HA tag
antibodies, and the lower is by anti-Actin antibodies. (D) The NA enzyme Km value of
the rgBR/59/07 viruses of GA06-NA variants of the 4 single substitutions by enzyme
kinetics assay. In all graphs, all values are the mean of 3 determinations ± SD.
*, ** P<0.05 by t test when compared to GA06-wt or GA06-H275Y respectively.
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Figure 3-12. The plaque morphology of rgBR/59/07 viruses by using variant GA06NA genes with different single amino acid substitutions.
The plaque morphologies of the rgBR/59/07 viruses by using 10 variants of GA06-NA
gene with 4 different single amino acid substitutions at the absence or presence of the
H275Y mutation respectively. The mutation sites were shown above each image.
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Regarding the enzyme activity of the GA06-NA variants of the single amino acid
substitutions (Fig 3-11B), the H275Y mutation in the GA06-NA further decreased its
intrinsically-low enzyme activity, as shown above. The R222Q or E329K substitution
alone in the GA06-NA significantly increased enzyme activities (p<0.05), although to a
smaller degree with the presence of the H275Y mutation. The V234M or D344N
substitution alone in the GA06-NA slightly increased the enzyme activities, but at the
presence of the H275Y mutation, both substitutions essentially alleviated the loss of the
activity caused by H275Y mutation.
We examined if the 4 amino acid substitutions in the GA06-NA increase the
enzyme activity by the mechanisms we identified above and we firstly determined their
effects on total protein expression level of the GA06-NA (Fig 3-11C). As shown above
(Fig 3-3B), the protein expression level of GA06-NA was naturally-low, and the H275Y
mutation in the GA06-NA aggravated the low expression level to an even lower level.
Both R222Q and V234M substitution alone in the GA06-NA greatly increased the
protein expression levels, even with the presence of the H275Y mutation. The E329K and
D344N substitutions in the GA06-NA did not show any evident effect on protein
expression. The results on protein expression were consistent with the roles of the 4
markers we identified in the BR07-NA as above.
We also tested the effects of the 4 substitutions in the GA06-NA on the enzyme
Km value (Fig 3-11D). The Km value of the GA06-NA was intrinsically high as shown
above (Fig 3-3D), and the H275Y mutation in the GA06-NA significantly raised the
inherently high Km value to a higher degree (p<0.05). The R222Q, E329K and D344N
substitutions alone in the GA06-NA significantly lowered the Km values respectively
(p<0.05), but to a smaller degree with the presence of the H275Y mutation. The V234M
substitution in GA06-NA did not show any impact on the Km value. The results on the
enzyme Km value were consistent with roles of the 4 markers we identified in the
BR07-NA as above.
In conclusion, by using a reciprocal substitution strategy in the GA06-NA, we
found that in the genetic background of the NC99-like NAs, the R222 and V234 two
residues were responsible for the low level of NA protein expression, and the R222, E329
and D344 three residues accounted for the low NA enzyme affinity to substrate binding.
Furthermore, the NC99-like NAs were not only inherently low in quantity and quality
due to the two groups of molecular markers, they also could not counteract the additional
diminishing effects of the H275Y mutation on the protein expression and enzyme affinity
and thus had no H275Y tolerance. On the other hand, each of the four reciprocal
substitutions in the NC99-like NA partially but significantly increased the enzyme
activity by increasing the protein quantity and/or quality. More importantly, the improved
NA quantity and quality by the 4 reciprocal substitutions in the NC99-like NA partially
counteracted the deleterious effects of the H275Y mutation on protein expression and
enzyme affinity, and conferred at least partial degree of tolerance to the H275Y mutation.
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Determination of the Timeline of Fixations of the Four Molecular Markers during
Evolution of N1 NA Genes
Now that we have identified that each of the 4 amino acid substitution (R222Q,
V234M, K329E, D344N) in the NC99-like NA can partially but significantly improve the
NA protein quantity and quality, we then sought to uncover the temporal sequence of the
fixation of the four molecular markers into the NA gene during seasonal N1 evolution,
and to understand if the sequential addition of all four molecular makers could fully
reconstruct the quantity and quality of the NC99-like NAs to the level equivalent to those
of the BR07-like NAs.
The phylogenetic analysis with incorporation of a temporal scale and a
probabilistic analysis were used to determine the relative timeline of the fixation of each
of the 4 molecular markers (Fig 3-13). The 354 position is of special interest for its
reversion between the two lineages, so it was also included along with the other four
positions for the analysis. First of all, the H275Y mutation appeared in a sporadic and
random fashion before 2007. Since then, the H275Y mutation was fixed into the majority
of the N1 populations especially during 2008~2009. Secondly, remarkably, all four
amino acid substitutions emerged and were fixed into the N1 population prior to the
fixation of the H275Y mutation; The 4 amino acid substitutions were fixed into the NA
gene in a sequential manner in the order of V234M - R222Q - D344N - K329E. Last,
puzzlingly, a G354D substitution firstly occurred during the NA divergence at 2005, but
later a D354G reversion arose, coincident with the fixation of H275Y mutation at 2008.
Taken together, the timeline analysis is consistent with the previous lineage consensus
residue analysis, but it is more informative as it provides evidence and insights about
when the naturally-occurring oseltamivir-resistant H1N1 viruses emerged and how their
emergence was associated with acquisition of the H275Y tolerance by the 4 molecular
markers.
Effects of Sequential Addition of the Four Molecular Markers into GA06-NA Genes
on Protein Function and Expression
To simulate the sequential fixation of 4 molecular markers during the NA
evolution history, we sequentially placed the 4 amino acid substitutions into the
GA06-NA gene one by one in an order indicated by the timeline analysis (V234M R222Q - D344N - K329E), with the absence or presence of the H275Y mutation. Then
we generated the reverse genetics viruses by using the 6 variants of the GA06-NA gene
and compared them with GA06-NA and BR07-NA derived viruses as described above.
As each of the four substitutions were added into GA06-NA sequentially, the virus
plaque size and the enzyme activity increased accordingly in a progressive way (Fig
3-14A, B, Fig 3-15), eventually to the degree fully equivalent to or even slightly higher
than those of BR07-NA when the fourth substitution was added. With the presence of the
H275Y mutation, the sequential addition of each substitution lead to the similar
progressive increase of plaque size and enzyme activity as that in the absence of the
H275Y mutation, but at a slightly small magnitude. More importantly, the sequential

65

Figure 3-13. The timeline of fixation of the 6 amino acid residue substitutions in the
seasonal N1 NA genes.
NA genes of representative 249 human seasonal H1N1 viruses were used for
phylogenetic analysis. The tree was constructed by using the Bayesian simulations
method. The probabilistic model was used to analyze of amino acid fixation by ancestral
state reconstruction. The trunk color change shows that the average population possesses
that particular amino acid residue indicated by the color code. Each tree is the same but
shows the fixation of the amino acid residues for each of the 6 amino acid positions of
NA proteins. The upper and lower arrow shows the time when the respective V234M and
H275Y were fixed into the population.
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Figure 3-14. Effects of sequential addition of four amino acid substitutions in the
GA06-NA genes on plaque size of reverse-genetics viruses, NA enzyme activity, NA
Km value and NA protein expression.
(A) The plaque sizes of the rgBR/59/07 viruses by using 10 variants of GA06-NA genes
with sequential addition of 4 different single amino acid substitutions with the absence or
presence of the H275Y mutation respectively. The enzyme activities (B) and protein
detection (C) of the 10 variant GA06-NA proteins with the sequential addition of 4
substitutions with the absence or presence of the H275Y mutation respectively. (C) The
upper panel is the detection by anti-HA tag antibodies, and the lower is by anti-Actin
antibodies. (D) The NA enzyme Km value of the rgBR/59/07 viruses of GA06-NA
variants with the sequential addition of the 4 substitutions by enzyme kinetics assay. The
order of the sequential addition is as V234M + R222Q + D344N + K329E. In all graphs,
all values are the mean of 3 determinations ± SD. *, ** P<0.05 by t test when compared
to GA06-wt or GA06-H275Y respectively.
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Figure 3-15. The plaque morphologies of rgBR/59/07 viruses by using variant
GA06-NA genes with sequential addition of the 4 amino acid substitutions.
The plaque morphologies of the rgBR/59/07 viruses by using 10 variants of GA06-NA
gene with 4 different single amino acid substitutions at the absence or presence of the
H275Y mutation respectively.
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addition at each step alleviated the degree of the loss of activity caused by the H275Y
mutation, and the addition of all four substitutions into GA06-NA eventually led to only a
marginal loss of the activity by H275Y mutation, equivalent to the minimal degree of
activity loss in the BR07-NA by the H275Y mutation.
We then examined the effects of the sequential addition of 4 amino acid
substitutions in the GA06-NA on the protein expression and enzyme affinity (Fig 3-14C,
D). The addition of the first two substitutions V234M and R222D into the GA06-NA not
only greatly increased the level of NA protein expression to that of BR07-NA, but also
effectively prevented the reduction of protein expression caused by the H275Y mutation.
The addition of the next two substitutions V344D and E329K didn’t show any further
impact on the protein expression. The first addition of V234M into the GA06-NA didn’t
cause a measurable change of the enzyme Km value, but the following addition of
R222D, V344D and E329K progressively and significantly reduced the enzyme Km
value (p<0.05), eventually to a level equivalent to that of BR07-NA. Moreover, the
sequential addition of the three substitutions also largely counteracted the diminishing
effect by the H275Y mutation on enzyme affinity, and eventually controlled the level of
enzyme affinity comparable to that of BR07-NA with the presence of the H275Y
mutation.
In summary, the sequential addition of the 4 amino acid substitutions (V234M R222Q - D344N - K329E) greatly increased the NA protein quantity and then
significantly increased the NA enzyme quality. There are 10 amino acid substitutions
differentiating between the genotype of NC99-like and BR07-like NAs, but sequential
addition of the 4 substitutions into the NC99-like NA was sufficient to reconstruct the
NA protein quantity and quality to a level equivalent to those of the BR07-like NA. More
importantly, the high NA protein quantity and quality by the 4 substitutions effectively
counteracted the diminishing effects of the H275Y mutation on the protein expression
and enzyme affinity, leading to only a marginal loss of the enzyme activity by the H275Y
mutation, thus successfully conferring tolerance to the H275Y mutation.
Determination of NA Tolerance to the H275Y Mutation in 2009 Pandemic H1N1
Viruses
In our previous study in Chapter 2, we characterized the transmissibility, growth,
and NA kinetics of a wild-type (DM/524/09) and a H275Y mutant (DM/528/09) 2009
pandemic H1N1 viruses (pH1N1), which only differed at the H275Y mutation. We found
that the H275Y mutant pH1N1 virus had lower transmissibility in ferrets, delayed growth
in cells and reduced NA affinity in vitro than the wild-type pH1N1, so we concluded that
the H275Y mutant pH1N1 virus had lower fitness relative to the wild-type pH1N1 virus.
In the present study, we identified that the NA tolerance to the H275Y mutation largely
determined the virus fitness level of H275Y mutant viruses in the seasonal H1N1 virus
lineage. Next, we sought to evaluate if and how the attenuated virus fitness in the H275Y
mutant pH1N1 virus was associated with the NA H275Y intolerance.
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NA gene comparison between the pandemic and seasonal H1N1 viruses. We
first examined and compared the consensus sequences of NA genes between seasonal and
2009 pandemic H1N1 viruses, specifically with a focus at the four amino acid positions
with permissive residues for the H275Y mutation (Table 3-2). There is ~25%
dissimilarity in amino acid residues compositions of the NA genes between seasonal
H1N1 and pH1N1 viruses, which is associated with their distant ancestor in N1 gene
evolution (22). We only listed the NA amino acid residues of pH1N1 viruses at the 10
positions at which the residues differentiate the NA genes of two seasonal N1 lineages,
which also showed great diversity from the seasonal lineages. By far, no predominant
difference was found in the NA genes between the wild-type and H275Y mutant pH1N1
viruses. With regards to the 4 amino acid positions permissive for the H275Y mutation in
seasonal N1 lineage, the NA genes of pH1N1 viruses showed both conservation and
diversity at the 4 positions. The NAs of pH1N1 viruses similarly encode V residue at the
234 position as the NC99-like NAs, which was linked to the inherently-low NA protein
expression. pH1N1 NAs encode N residue at the 344 site same as BR07-like NAs, which
was linked the inherently-high NA enzyme affinity; but pH1N1 NAs encode a different N
residue at 222 position other than the R or Q in seasonal NAs, and N residue at 329
position other than the E or K in seasonal NAs. Considering the extensive diversity in the
NA amino acid residue compositions between pH1N1 and seasonal H1N1 lineage, further
extensive investigation is needed to characterize what roles these distinct molecular
markers have in determining the NA protein quantity and quality respectively.
NA activity, protein expression and enzyme affinity of the wild-type and
H275Y mutant pandemic H1N1 viruses in vitro. Next, we evaluated if the NA protein
of the pH1N1 virus have the tolerance to the H275Y mutation or not in the level of NA
enzyme activity, protein expression level and enzyme affinity, in spite of the diverse NA
amino acid residues. Two pairs of NA proteins, the wild-type and H275Y mutant of
BR07-NA and GA06-NA were compared with the NAs of DM/524/09 and DM/528/09
viruses (DM09-NA) respectively regarding to NA tolerance to the H275Y mutation.
In the level of NA enzyme activity (Fig 3-16A), we compared the percentage loss
of enzyme activity in each H275Y mutant NA proteins relative to its respective matching
wild-type NA. The results showed the H275Y mutation caused loss of activity in the NA
proteins of all three lineages, with lowest magnitude in the BR07-NA (~20%), and the
greatest magnitude (~70%) in the DM09-NA which was even bigger than that in the
GA06-NA (~50%). The results suggested that the DM09-NA was not able to tolerate the
negative effects of the H275Y mutation on enzyme activity, with a huge loss of the
activity in the H275Y mutant of DM09-NA.
As for the NA protein expression (Fig 3-16B), the results showed that the protein
expression level of the wild-type DM09-NA was inherently lower than that of the
wild-type BR07-NA, and similar to that of the GA06-NA. The H275Y mutation further
greatly reduced the inherently-low level of total protein expression of the DM09-NA and
the GA06-NA, but hardly changed the level of the BR07-NA. The flowcytomerty
confirmed that the cell surface accumulation of the DM09-NA was also greatly
diminished by the H275Y mutation (Fig 3-16C). The results suggested that the
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Figure 3-16. The NA activities, protein expression and enzyme Km values of the
2009 pandemic H1N1 viruses.
(A) The percentage loss of enzyme activities of the H275Y mutant NA of the DM09
pandemic H1N1 virus relative to its wild-type NA, with comparison to the loss of activity
in BR07 and GA06 NA protein pairs. (B) The detection protein expression of the
wild-type and H275Y mutant of DM09-NA proteins, with comparison the loss of activity
in BR07 and GA06 NA protein pairs. The upper panel is the detection by anti-HA tag
antibodies, and the lower is by anti-Actin antibodies. (C) The surface protein
accumulation of DM09-NA proteins by flowcytometry. Black line indicates the wild-type
protein and red line indicates the H275Y mutant protein.
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DM09-NA was not able to tolerate the diminishing effects of the H275Y mutation on NA
protein expression, with greatly reduced protein expression of the H275Y mutant of
DM09-NA.
As regards to NA enzyme affinity to substrate binding, a retrospective
examination of the data in the previous and present studies (Table 2-1, Fig 3-7D) showed
the wild-type DM09-NA exhibited a slightly higher Km value than the wild-type
BR07-NA, suggesting its slightly lower enzyme affinity of substrate binding. The H275Y
mutation further increased Km value of the DM/09-NA with a bigger magnitude than that
of BR07-NA, but a smaller magnitude than that of GA06-NA. The results suggested that
the DM09-NA had naturally relatively low enzyme affinity and the H275Y mutation
further reduced its enzyme affinity. Although it is hard to determine if the DM09-NA had
the tolerance to H275Y mutation on enzyme affinity level or not, as the reduction of the
affinity was intermediate between the BR07-NA and GA06-NA, the H275Y mutation
still had a negative effect on the enzyme affinity of the DM09-NA.
In summary, the significant loss of the enzyme activity in the H275Y NA of the
pH1N1 virus was caused by greatly reduced NA protein expression as well as reduced
NA enzyme affinity by the H275Y mutation, which suggested the NA of pH1N1 virus
now had no tolerance to the H275Y mutation. The NA intolerance to the H275Y
mutation on the NA protein level correlated well with the lower virus fitness of the
H275Y mutant pH1N1 virus than that of the wild-type pH1N1 virus, and further
explained the delayed growth in cells and the transmissibility of the H275Y pH1N1 virus
in ferrets.
Discussion
About the unorthodox naturally-occurring osletamivir-resistant seasonal H1N1
viruses, one of biggest questions remained is what fundamental changes occurred in the
NA genes and consequently in the NA proteins of the H1N1 viruses over the first decade
of oseltamivir use. The findings of two permissive NA mutations enabling the evolution
of H275Y mutant viruses significantly advanced our understanding of the defects caused
by the H275Y mutation on the NA proteins, but it still left the question pending about
what was the intrinsic changes or evolvement in the NA genes and proteins of the
seasonal H1N1 viruses other than the defects caused by the H275Y mutation. This study,
to our knowledge, is the first to understand how the genetic and phenotypic divergence of
the NA proteins by themselves can allow the fixation of the H275Y mutation into the NA
proteins during the NA evolution history, apart from understanding the defects caused by
the H275Y mutation, which is underlying NA molecular basis of the naturally-occurring
oseltamivir-resistant H1N1 viruses.
By integrating NA genotype evolution with the consequent NA protein phenotype
evolvement, we uncovered the at least some monumental “scenes” when the fundamental
changes in NA genes and proteins occurred during the evolution of the seasonal H1N1
viruses : 1) in the earlier years between 1999~2006, a lineage of human H1N1 viruses
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called NC99-like viruses were the predominant circulating. The NC99-like NA proteins
were inherently low in quantity and quality (protein expression and enzyme affinity), and
the presence of the H275Y NA mutation could further diminish the inherently-low
quantity and quality, which was destructive for the NA function. As the NC99-NAs
cannot tolerate the presence of H275Y mutation on protein level, the H275Y mutant
viruses had lower virus fitness level than the wild-type viruses. Owning to this reason,
during that time, the NC99-like H275Y mutant viruses occasionally emerged under drug
selection pressure, but the H275Y mutant viruses were soon extinguished by the
wild-type viruses once the drug selection pressure was removed. 2) During the continuing
H1N1 virus evolution, the NC99-like H1N1 viruses were gradually acquiring amino acid
substitutions in NA genes as well as in HA genes. Starting from around 2003, the
NC99-like NA genes sequentially acquired V234M and R222D substitution, which
greatly enhanced the NA protein expression level; following that, the NA genes
subsequently accumulated V344D and E329K substitutions, which significantly
increased the NA enzyme affinity to substrate binding. 3) After the years, the sequential
addition of a total of ten amino acid substitutions including the four function-altering
substitutions into the NC99-like NA genes eventually led to emergence of a new lineage
of NA genes and corresponding viruses at 2007, the BR07-like H1N1 viruses. The
BR07-like NA proteins were naturally high in protein quantity and enzyme quality as a
result of the four amino acid substitutions; more importantly, the high NA quantity and
quality were able to counteract the negative effects of the H275Y mutation on the protein
expression and enzyme affinity, and the function level of the BR07-like NA proteins was
largely preserved with only a marginal loss; as the BR07-like NA proteins can tolerate
the presence of the H275Y mutation on the protein level, the BR07-like H275Y mutant
viruses retained a virus fitness level comparable to the wild-type viruses; thus they were
able to continue circulation with wild-type viruses in the absence of the drug selection
pressure until 2009 season before swine-origin pandemic influenza viruses took over the
world.
In our opinion, we stress the NA genetic divergence from NC99-like into
BR07-like H1N1 viruses including the acquisition of the 4 molecular markers in the first
place was associated with NA protein antigenic drift. Among the 10 positions at which
the amino acid differentiates the two NA lineages, 3 positions (222, 249, 344) correspond
to antibody recognition sites in the N2 NA protein (130-132) and the mutations at these
three positions (Q222R, 249G, N344D) in the NA of BR/59/07 virus affected the
reactivity of the different anti-sera to the virus in NA inhibition assay (133). The 329
position was also suggested as a potential subdominant conserved epitope because
E329K mutation in the NA of BR/59/07 virus was very important for the NA protein
recognition by the human sera (133). It is uncertain if other 6 positions are also involved
in antigenic sites and further understanding of N1 NA protein antigenic sites is needed.
Nevertheless, among the 4 molecular markers we identified, three of them (222, 344,
329) has been showed to be involved in NA antigenic determinants. In the NA molecular
structure, all these three positions are at the surface of NA globular head distant from the
NA active site, and they are all at the opposite side to the tetramer interface (Fig 3-2)
(133). Theoretically, the structure locations of these three positions potentially allow their
access to antibody or substrate binding. We are uncertain how to connect the
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simultaneous changes in both NA antigencity and NA enzyme activity caused by the
same amino acid residues in molecular level, and precise NA structures with different
residue substitutions are required for answers to this question.
It should be stressed that the natural force driving the divergence of NA genes of
the H1N1 viruses most likely is the host immunity against NA protein. The host
immunity can target the virus surface protein HA and NA during infection and herd
immunity against the two proteins accumulates over a time of circulation of the viruses.
To evade the herd immunity against the proteins, both HA and NA genes constantly
evolves by acquiring mutations at the antigenic sites, known as antigenic drift (134). On
the other hand, an intriguing hypothesis about NA evolution is that NA genes may
co-evolve with HA genes (27). HA proteins may be subject to more host immunity
pressure than NA proteins, as HA protein binds to the sialic acid-containing receptors and
neutralization of HA proteins by host immunity can annul the virus replication in hosts.
Considering the receptor-binding activity of HA and opposite receptor-destroying activity
of NA, the fast evolving HA genes may necessitate co-evolution of NA genes to acquire
an optional HA-NA balance for efficient virus replication and transmission. Some studies
have showed that the phylogeny of the HA genes exhibited the same cluster pattern as the
NA genes in the seasonal H1N1 viruses (63-65). The matched cluster patterns of the HA
and NA genes may reflect the paralleled co-evolution of the two genes and matched
function levels of the two proteins in the viruses. Nevertheless, the NA divergence of
NC99-like to BR07-like firstly is associated with antigenic drift, and the genetic changes
of the NA gene may result in potential changes in other protein phenotypes, such as
protein expression and function identified in our case.
It also should be stressed that the accumulation of the four NA molecular markers
during the natural NA gene divergence from NC99-like into BR07-like is most likely just
fortuitously beneficial for the H275Y mutation. The four molecular markers can
determine the low or high quantity and quality of NA proteins of the two lineages, but the
terms of “low” or “high” are only relative between the two lineages. NA proteins neither
being “low” nor “high” is a defect for the proteins to function as a part of whole
infectious virus particle. In the present study, the wild-type NC99-like virus and
BR07-like virus the virus exhibited the equivalent growth and transmissibility in the
naive ferrets, which suggested that NC99-like viruses were not inferior to BR07-like
viruses in the naïve hosts in terms of infectivity and transmissibility in spite of their
“low” NA quantity and quality, and vice versa. The sustained circulation of the
NC99-like viruses from 1999~2006 also suggests that the “low” NA quantity and quality
is not a defect for the viruses themselves. The extinguishment of the NC99-like viruses
by replacement of the BR07-like viruses primarily was the result of antigenic drift due to
the accumulated herd host immunity against the NC99-like viruses over the extended
circulation. BR07-like NA proteins being “high” quantity and quality are only
fortuitously beneficial or “permissive” for the tolerance of the H275Y mutation. Only
when the H275Y mutations were introduced into the NA protein, the H275Y mutation
had differential effects on the NAs proteins, then the superiority of NA proteins regarding
to the tolerance to the H275Y mutations can be separated. The “low” quantity and quality
of the NC99-like NAs cannot tolerate the H275Y mutation, but the “high” quantity and
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quality of the BR07-like NAs can tolerate the H275Y mutation. In other words, if the
H275Y mutation had never emerged, the quantity or quality of the NAs would not have
made a difference for the infectivity and transmissibility of the viruses. Concisely, the
four NA molecular markers we identified here are 1) the residues associated with NA
protein antigenic drift, 2) the residues associated with NA function in terms of protein
quantity and enzyme quality, and 3) the residues associated with the tolerance to the
H275Y mutation on NA proteins.
In addition to the four NA molecular markers as described above, the NA 354
position is of a unique genotype and functional role during the NA evolution of the H1N1
viruses. Regarding the genotype of the position, during the NA divergence from the
NC99-like into the BR07-like lineage, the amino acid residues were firstly substituted as
G354D; then within the BR07-like lineage, it was exactly reversed as D354G in the
majority of the H275Y mutant viruses, but remained unchanged as D in all the wild-type
viruses within the lineage. As regards to its functional role, the D354G slightly increased
the NA activity in the BR07-NA, which is exactly opposite to other four substitutions in
the BR07-NA (from BR07-like to NC99-like) that all reduced the NA activity. Moreover,
unlike the other four positions, the D354G somehow increased the NA activity but not
through the change in protein expression or enzyme affinity. By our results, it remains
unknown why the NC99-like NAs sequentially acquired the four substitutions to increase
their NA activity, but then adopted G354D which apparently functioned opposite to NA
activity. In spite of the enigmatic initial G354D substitution during the lineage switch, the
later D354G reversion coinciding with H275Y mutation within the BR07-lineage seemed
to have further increased the enzyme activity of H275Y mutant NAs and thus have
repaired the marginal loss of NA activity caused by the H275Y mutation, which suggests
that the later D354G reversion is also a beneficial mutation for the NA function in the
H275Y mutant viruses.
In the timeline of the fixation into NA genes, especially relative to the fixation of
the H275Y mutation, the D354G reversion is of unique standing different from the other
four molecular markers in N1 evolution history. In the timeline the four molecular
markers arose sequentially between 2002~ 2006 during the NA divergence toward the
BR07-like lineage, and the puzzling G354D substitution occurred around 2005~2006 at
later stages of the divergence while the D354G reversion coincided or closely followed
the fixation of H275Y mutation within the BR07-like lineage at 2008. By the integration
of their relative fixation time and the respective function of the five molecular makers,
we are able to further differentiate the unique role of the D354G reversion from the other
four molecular markers. From a point of view of the molecular evolution of multiple
mutations (67;135), the later D354G reversion can be better described as a
“compensatory” mutation, which followed the major functional mutation (the H275Y
mutation in this case) and it might be selected to aim to repair the function damage
caused by the major functional mutation. Whereas the other four molecular markers
rather better be classified as “permissive” residues, which occurred initially prior to the
major functional mutation (the H275Y mutation), but were fortuitously beneficial for the
major functional mutation.

75

The NA tolerance to the H275Y mutation at the protein level conferred by both
the “permissive” residues and the “compensatory” mutation had profound ramification on
virus fitness level. It is worth noting that virus fitness describes its adaptation or relative
ability to produce infectious progeny in a host (39). A key concept about virus fitness is
“relative”. Although originally a growth competition experiment between different
viruses is used to define the fitness level of a virus relative to another virus (39), now, as
an alterative, a comparative experiment between different viruses generally can be used
to describe the fitness level of a virus relative to another virus. In our discussion, the
“relative” is between wild-type and H275Y mutant viruses. The comparative virus
infectivity and transmissibility etc all can demonstrate the virus fitness level relative to
each other. In previous report at 2002, an H275Y resistant variant exhibited severely
compromised replication and virulence both in vitro and in vivo compared with the
wild-type virus (54;55), suggesting compromised fitness of the H275Y virus, presumably
a NC99-like virus, relative to the wild-type virus. While in more recent studies, the
replication of the recent BR07-like H275Y mutant viruses was not impaired in cells and
ferrets compared to the wild-type viruses (61), suggesting uncompromised fitness of the
viruses relative to the wild-type viruses. In our present study, we explicitly demonstrated
that the replication and transmissibility of the NC99-like H275Y viruses in ferrets was
significantly attenuated, while those of the BR07-like H275Y viruses were minimally
altered, when compared with those of their counterpart wild-type viruses. The results
clearly suggested the distinct fitness level of the H275Y mutant viruses relative to the
corresponding wild-type viruses in the two lineages. The present study is closely
correlated with the previous reports, which strongly supported that the NA intolerance or
tolerance to the H275Y mutation in protein level largely determined the fitness outcome
of the H275Y mutant viruses relative to the wild-type virus.
The viral fitness of H275Y mutant viruses relative to wild-type viruses also can
be illustrated by epidemiology data about their respective prevalence in circulation. The
circulation prevalence of different viruses can be an ultimate manifestation of the virus
fitness relative to each other in nature. Based on the surveillance studies of NA inhibitor
susceptibility, between 1999~2006, there were extremely low prevalence of H275Y
mutant influenza viruses among the globally collected influenza virus isolates (from
0~1.7%) (32;46;48), suggesting that the H275Y mutant viruses had lower fitness
advantage than the wild-type viruses and thus were extinguished from circulation at the
time. However, between 2007 to 2009 pre-pandemic season, the H275Y mutant viruses
were detected of global high prevalence in the context of absence of the drug treatment
(45;56), even with a trend to override the wild-type viruses to become the dominant
viruses, suggesting that the H275Y mutant viruses had equivalent or even higher fitness
advantage than the wild-type viruses and thus were sustained in circulation. Notably, the
timeline of the contrasting prevalence level of H275Y mutant viruses is also in
accordance with the timeline of the circulation of NC99-like and BR07-like H1N1
viruses, which also in accordance with our findings that the distinct fitness level of
H275Y mutant viruses in the two lineages.
With the identification of the NA molecular basis including both “permissive”
markers and “compensatory” mutations in the naturally-occurring H275Y resistant
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viruses, a retrospective look allows us to have a better understanding about the variations
of the transmissibility of the H1N1 viruses in ferrets. In the BR07-like group, both
HW/28/07 and rgBR/59/07-NAH275Y H275Y mutant viruses exhibited slightly delayed
direct-contact transmission but essentially uncompromised transmissibility compared to
the wild-type virus. Now the delay can be correlated to a common feature in their
genotypes that both viruses possessed all 4 permissive markers but lacked the
compensatory mutation D354G in their NA protein. The NY/3467/09 virus H275Y
mutant also exhibited slightly delayed direct-contact transmission and this virus had the
lowest NA enzyme affinity among the tested BR07-like viruses. Now both phenotypes
can be correlated to the absence of the permissive D344N in its NA protein, although it
had acquired the 3 permissive markers and the compensatory mutation. Both the
NY/1672/09 and rgBR/59/07-NAH275Y+D354G H275Y mutant viruses exhibited the
transmissibility equivalent to the wild-type virus in terms of efficiency and dynamics,
which now can be correlated to the possession of all 4 permissive markers and the
compensatory mutation in their NA proteins. In the NC99-like group, the severely
attenuated transmissibility of GA/20/06 H275Y mutant virus now can be explained by the
absence of entire 4 permissive markers in its NA protein. The MI/03/02 H275Y mutant
virus also exhibited greatly attenuated transmissibility, which can be associated with the
absence of the two permissive markers in its NA protein. This virus had acquired two
permissive markers R222Q and D344N in its NA gene and its NA enzyme activity was
the highest in the tested NC99-like NAs, so its attenuated transmissibility suggested that
partial acquisition of the permissive markers was not sufficient to tolerate the negative
effects of the H275Y mutation, and all four permissive markers might be required for the
full tolerance to the H275Y mutation.
The contrasting difference in the transmissibility of two aberrant H1N1 viruses
NY/3467/09 and MI/03/02 viruses also suggested that there might be a function hierarchy
among the four NA permissive molecular markers in terms of their permissive degree to
the H275Y mutation. The residues composition at the four positions in the NA genes of
NY/3467/09 and MI/03/02 viruses is aberrant from the sequential addition order
suggested by our analysis (V234M - R222Q - D344N - K329E). The transmissibility of
the NY/3467/09 virus was essentially uncompromised only with early delay, in spite of
the absence of the D344N substitution in its NA gene. However, the transmissibility of
the MI/03/02 virus was still greatly attenuated in spite of the presence of the two
permissive markers R222Q and D344N in its NA protein. The distinct transmissibility of
the two viruses suggested that degree of the “permissiveness” of the four molecular
markers to the H275Y mutation may be different, although each of them played a
significant role in the NA protein function. It also suggested that all four of them were
required to confer NA protein full tolerance to the H275Y mutation to maintain unaltered
virus fitness (transmissibility). By our results, although the D344N significantly increased
the NA function, the D344N alone may only exert a small degree of “permissiveness” to
the H275Y mutation as its absence in the NY/3467/09 virus seemed to have not
attenuated the transmissibility of the viruses, and its presence in the MI/03/07 virus
seemed to have not rescued the transmissibility of the virus. The functional hierarchy of
the four permissive mutations doesn’t necessarily correlate with the temporal sequence of
the fixation of the four mutations, and further elucidations are warranted.
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With regards to the temporal sequential order for the four permissive molecular
markers, we are uncertain of the underlying mechanism that prompted the first selection
of the V234M during the NA divergence from NC99-like to BR07-like lineage. We
showed that the V234M could increase the NA activity by increasing the NA protein
expression, and all other three activity-increasing NA molecular markers appeared after
the V234M. Apparently, the first appearance of V234M substitution made the NA protein
promiscuous for more subsequent substitutions, especially the accumulation of
activity-increasing NA substitutions. The underlying mechanism for such molecular
selection is to be elucidated.
We also point out that the NA molecular basis most likely is not the only
molecular basis in the naturally-occurring H275Y resistant H1N1 viruses and we do not
exclude the possible roles of other proteins in the emergence and spread of the naturally
resistant H1N1 viruses. During 2008~2009, especially at the 2009 pre-pandemic season,
the epidemiology data showed a trend that H275Y mutant viruses were overriding the
wild-type viruses and becoming the dominant circulating viruses(45;56), suggesting that
the H275Y mutant viruses had acquired better fitness including higher transmissibility
than the wild-type viruses at the time. In the present study, we also noticed that both the
NY/1602/09 and rgBR/59/07-NAH275Y+D354G H275Y mutant virus possessed the four
permissive markers and the compensatory mutation, but their transmissibility had subtle
differences: the NY/1692/07 virus had apparently faster transmission dynamics than the
wild-type virus, but the later had the same transmission as the wild-type virus. Therefore,
although our findings of the NA molecular basis largely explain why the
rgBR/59/07-NAH275Y+D354G virus was not compromised compared to the wild-type
viruses, it cannot explain why the NY/1692/09 virus exhibited even higher
transmissibility than the wild-type virus, which is exactly in line with the trend of H275Y
mutant viruses in 2009 season. It suggests that the naturally resistant viruses could have
acquired more advantageous fitness through other mechanisms potentially by other
proteins, which made them even more “fit” than wild-type viruses and overriding in
circulation. Other studies have shed some clues, such as some HA amino acid
substitutions promoting the replication of the resistant viruses, and some intra-subtype
inter-clade segment reassortment events associated with the naturally resistant viruses
(65;66;136). Further studies of the molecular basis other than NA in the
naturally-occurring resistant viruses are warranted.
One important implication of this study is its relevance to the H275Y
mutation-caused resistance in the currently circulating swine-origin 2009 pandemic
H1N1 (pH1N1) viruses. As for the virus fitness of H275Y mutant pH1N1 viruses, our
study showed that a H275Y mutant pH1N1 viruses exhibited lower fitness than its
counterpart wild-type pH1N1 virus including its less efficient transmissibility in ferrets
and delayed growth in cells. In the NA molecular level, the attenuated virus fitness was
well explained by significantly reduced NA enzyme activity due to greatly diminished
protein expression and reduced enzyme affinity. The results strongly suggested that the
NA of the pH1N1 virus had little tolerance to the H275Y mutation. However, we want to
be very cautious to extend our findings and definition of the H275Y tolerance to the
pH1N1 NA. We have discovered the NA H275Y tolerance at the levels of NA enzyme
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activity, NA protein expression and NA enzyme affinity in H1N1 viruses of different
lineages, but a perceptive standard needs to be further explored about how much degree
of loss of activity, protein expression or enzyme affinity caused by the H275Y mutation
can be defined as between tolerance and intolerance to the H275Y mutation. In the case
of the NA of the H275Y mutant pH1N1 virus, the greatly reduced protein expression was
rather conspicuous and could be easily defined as the intolerance to the H275Y at the
protein expression level, but the magnitude of decrease of the enzyme affinity was
between those of the BR07-like viruses and the NC99-like viruses, thus the conclusion
remained ambiguous about the intolerance or tolerance to the H275Y at the enzyme
affinity level. Moreover, with regards to the NA molecular basis for the tolerance to the
H275Y mutation, we found the four permissive molecular markers (V234M, R222Q,
D344N, K329E) and one compensatory mutation (D354G) in the NA genes seasonal
H1N1 viruses. As seasonal N1 genes and 2009 pandemic N1 genes had distant ancestors
(22), the questions remains uncertain if these markers play the same roles in NA proteins
of pH1N1 viruses or if other amino acid residues can play similar roles. In the pH1N1
viruses, we have seen the difficulty to answer the questions, because the NAs showed
diverse amino acid residues at some positions other than the ones we identified in
seasonal NAs. How these variant amino acid residues can affect the NA protein
expression or function warrants additional studies.
Our findings about NA tolerance to the H275Y mutation also have implication on
the surveillance monitoring of the NA inhibitor resistance, especially the H275Y
mutation-caused resistance. Our study underlines the necessity of not only continuous
monitoring of drug resistance rates and but also characterization of evolving NA proteins.
Our study showed that the H275Y mutant pH1N1 virus had lower fitness than the
wild-type pH1N1 virus due to the NA intolerance to the H275Y mutation at the protein
expression level, which is still in line with the low the detection rate (1~3.5%) of H275Y
mutant pH1N1 viruses in surveillance studies so far (73). However, some studies have
found un-attenuated H275Y mutant pH1N1 viruses in animal models (87;88), and several
cases have identified community-transmitted H275Y mutant pH1N1 viruses (73;75-78).
In view of the precedent example of how the wild-type seasonal H1N1 viruses became
the naturally-occurring oseltamivir-resistant H1N1 viruses by acquisition of only the four
“permissive” molecular markers, it can be foreseen that the pH1N1 viruses also become
the same naturally resistant through a similar NA evolution path. The question if pH1N1
viruses have started its path to become naturally resistant needs to be further evaluated.
Ideally, we need closely monitor pH1N1 NA genotype divergence and investigate the
corresponding changes in NA protein phenotypes. If the genotype of pH1N1 NA were
found diverged, any big conspicuous changes associated with the genetic change
including the NA activity, protein expression and enzyme affinity should raise an alarm
about their possible acquisition of tolerance to the H275Y mutation. Further studies of
these newly isolated H275Y mutants of H1N1/2009 viruses are warranted, and the
community-transmitted H275Y mutant pH1N1 viruses will be of special merit for the
investigation.
In summary, the present study uncovered how the NA proteins of the seasonal
H1N1 viruses diverged during the evolution in terms of timeline, protein level attributes,
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and more importantly, the tolerance to the H275Y NA mutation. This study is of
significance to understand the NA molecular basis for the emergence and spread of the
naturally-occurring oseltamivir-resistant H1N1 viruses, and of important implication on
the surveillance monitoring of the virus susceptibility to NA inhibitors. Current epidemic
viruses continue evolving under selection pressure, therefore, such monitoring is essential
for public health, as NA inhibitors remain the primary therapeutic option for influenza
virus infection.
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CHAPTER 4.

METHODS

Compounds
The NA inhibitors oseltamivir carboxylate ([3R,4R,5S]-4-acetamido-5-amino-3[1-ethylpropoxy]-1-cyclohexene-1-carboxylic acid) and zanamivir (4-guanidinoNeu5Ac2en) were provided by Hoffmann-La Roche, Ltd. (Basel, Switzerland). The
compounds were dissolved in distilled water and aliquots were stored at –20 °C until the
time of use.
Cells
Madin-Darby canine kidney (MDCK) cells and human embryonic kidney cells
transformed with large T antigen (293T cells) were obtained from American Type
Culture Collection (ATCC, Manassas, VA). MDCK cells were maintained in minimal
essential medium (MEM) supplemented with 5% fetal bovine serum (FBS), 5 mM
L-glutamine, 0.2% sodium bicarbonate, 100 U/ml penicillin, 100 Pg/ml streptomycin
sulfate, and 100 Pg/ml kanamycin sulfate. 293T cells were maintained in opti-MEM
(Invitogen) supplemented with 5% FBS and antibiotics as above. MDCK cells
transfected with cDNA encoding human 2,6-sialyltransferase (MDCK-SIAT1 cells) were
kindly provided by Dr Mikhail N. Matrosovich and maintained as described previously.
Baby Hamster Kidney (BHK) cells were kindly provided by Dr. Charles Russell and
maintained as described previously (137). The Normal Human Bronchial Epithelial
(NHBE) cells (Lonza, Basel, Switzerland) were cultured on an air-liquid interface in
12-well plates and the infection with influenza viruses was described as previously (138).
For growth curve, the inoculums were added to the apical surface of cells and were
removed after 1 h of incubation at 37 ÛC. Apical supernatants containing progeny viruses
were collected by adding fresh medium into apical compartment 30 mins prior to the
indicated time point and stored at –70°C for further titration in MDCK cells All the cell
lines were maintained in a humidified atmosphere of 5% CO2 at 37 ºC.
Viruses
A panel of pandemic H1N1 and seasonal H1N1 influenza viruses of which the
NA genes were previously sequenced and published on Genebank was chosen for the
studies (Table 2-1 and Table 3-2). Among them, pandemic A/Denmark/524/2009 virus
(DM/524/09) and A/ Denmark/528/2009 virus (DM/528/09) were provided by Statens
Serum Institute, Copenhagen, Denmark. A/New York/3467/2009 virus (NY/3467/09) and
A/New York/1692/2009 virus (NY/1692/09) were provided by Wadsworth center of the
New York state department of health. Wild-type or NA H275Y mutant of
A/Mississipii/03/2002 virus (MI/03/02) was provided by the Neuraminidase Inhibitor
Susceptibility Network. All the rest of viruses such as A/Brisbane/59/2007 virus
(A/BR/59/09), A/Hawii/28/2008 virus (HW/28/08), A/New Jersey/15/2007 virus
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(A/NJ/15/07), A/Georgia/17/2006 virus (GA/17/06), A/Georgia/20/2006 virus
(GA/20/06), A/Memphis/13/2006 virus (MEM/13/06) etc viruses were provided by U.S
Centers for Disease Control and Prevention. Stocks of the H1N1 viruses were prepared in
MDCK cells. Upon receiving the viruses, all strains of virus underwent a limited number
of (1~2) passages in MDCK cells to maintain their original properties.
Virus Sequence Analysis
Viral RNA was isolated by using the RNeasy Mini kit (Qiagen, Valencia, CA).
Samples were reverse-transcribed and analyzed by PCR using primers specific for the
NA gene segment, as described previously (139). Sequencing was performed by the
Hartwell Center for Bioinformatics and Biotechnology at St. Jude Children’s Research
Hospital. The DNA template was sequenced by using rhodamine or dRhodamine dye
terminator cycle-sequencing Ready Reaction kits with AmpliTaq DNA polymerase FS
(Perkin-Elmer, Applied Biosystems, Inc., Foster City, CA) and synthetic
oligonucleotides. Samples were analyzed in a Perkin-Elmer Applied Biosystems DNA
sequencer (model 373 or 377). DNA sequences were completed and edited by using the
Lasergene sequence analysis software package (DNASTAR, Madison, WI).
Plasmid Construction and Site-directed Mutagenesis
The full length cDNA of 8 segments of BR/59/07 virus, and NA segments of
GA/17/06 and GA/20/06 viruses were cloned into the pHW2000 plasmid vector for
generation of reverse-genetics viruses in cells, as described previously (140). The
respective mutations indicated in the results were introduced into the corresponding NA
genes by using QuickChange site-directed mutagenesis (Stratagene, La Jolla, CA) and
confirmed by Sanger sequencing. Selected NA genes listed in the results were also coned
into the pCAGGS plasmid vector for expression of recombinant proteins in cells, as
described previously (137). The HA epitop-tag sequence were added into the primer
sequences to express the epitop-tagged NA protein by the vector.
Generation of Reverse-genetics Influenza Viruses
Reverse-genetics viruses were rescued by transfecting the PHW2000 plasmids
containing 8 influenza segments into 293T/MDCK cells co-culture, as describe
previously (141). Variant NA segments listed in the results were used together other 7
segments from BR/59/07 virus respectively for rescuing the viruses. One passage of the
rescued supernatant in MDCK cells (at MOI of 0.001~0.01) were used to prepare stocks
of all reverse-genetics viruses.
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Generation and Detection of Recombinant NA Proteins
Recombinant NA proteins were generated by transfecting the respective pCAGSS
plasmids into BHK cells, as described previously (137), and the protein expression was
detected by western blot or flowcytometry. Generally, for the proteins which needed
comparison among them, the same amount of each pCAGGS plasmid was transfected
into respective wells of BHK cells in parallel. Then the cell pellet was harvested at same
time in parallel, usually 24 hour post transfection for further analysis. For following
analysis, the same amount of cells were used and assayed in parallel. Anti-HA epitope
monoclonal antibodies (Sigma) were used for the detection of the recombinant proteins in
flowcytometry or webstern blot, as described previously (142) . Anti-Actin monoclonal
antibodies were used for detection of ȕ-Actin (Sigma) in the cells for normalization
purpose. The pCAGGS plasmids of different NA gene variants are as indicated in the
results.
Determination of Infectivity of Influenza Viruses
The 50% tissue culture infectious dose (TCID50) was determined in MDCK cells.
The cells were infected with serial log dilutions of the stock viruses, incubated for 1 h at
37ºC, washed, and overlaid with infection medium (MEM with 0.3% BSA and 1 Pg/ml
TPCK-trypsin). Infection of cells was determined by hemagglutination assay (HI) after
incubation for 3 d at 37°C, and TCID50 was calculated by the Reed-Muench method. The
plaque assay was used to determine the plaque forming unit (pfu) in a virus stock.
Confluent MDCK cells were incubated for 1 h at 37ºC with 10-fold serial dilutions of
virus in 1 ml of infection medium. The cells were then washed and overlaid with freshly
prepared MEM containing 0.3% BSA, 0.9% bacto-agar, and 1 μg/ml TPCK trypsin. The
plaques were visualized after incubation at 37ºC for 3 d by staining with 0.1% crystal
violet solution containing 10% formaldehyde.
Replication Kinetics
Single-step or multi-step growth curves were generated for influenza viruses in
MDCK cells. For single-step growth curve, confluent cell monolayers were infected with
viruses at a multiplicity of infection (MOI) of ~ 2.0 PFU/cell. After incubation, the cells
were washed with 0.9% aqueous NaCl solution (pH 2.2) to remove free infectious virus
particles and then were washed twice with phosphate-buffered saline (PBS) to adjust the
pH. Supernatants were collected 2, 4, 6, 8, 10 and 12 h p.i. and stored at –70°C for
titration. To generate multi-step growth curves, MDCK cells were infected with viruses at
an MOI of 0.001 PFU/cell. Supernatants were collected 12, 24, 36, 48, 60 and 72 h p.i.
and stored at –70°C for titration.
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Virus Susceptibility to NA Inhibitors
The viral NA activity was determined first by a modified fluorometric assay using
the fluorogenic substrate 2’-(4-methylumbelliferyl)-Į-D-N-acetylneuraminic acid
(MUNANA) (Sigma-Aldrich). The fluorescence of the released 4-methylumbelliferone
was measured in a Synergy 2 multi-mode microplate reader (BioTek) using excitation
and emission wavelengths of 360 and 460 nm, respectively. The drug concentration
required to inhibit 50% of the NA enzymatic activity (IC50) was determined by plotting
the percent inhibition of NA activity as a function of compound concentration calculated
in the GraphPad Prism 4 software from the inhibitor-response curve. The NA
inhibitor-sensitive A/Fukui/20/04 (H3N2) influenza virus was included in every plate for
comparison.
NA Enzyme Kinetics
All H1N1 viruses were standardized to an equivalent dose of 106.0 PFU/ml. We
measured NA enzyme kinetics at pH 6.5 with 33 mM 2-(N-Morpholino) ethanesulfonic
acid hydrate (MES; Sigma-Aldrich), 4 mM CaCl2, and MUNANA with a final substrate
concentration of 0 to 800 ȝM. The reaction was conducted at 37°C in a total volume of
50 ȝl, and the fluorescence of released 4-methylumbelliferone was measured every 60 sec
for 60 min in a Synergy 2 multi-mode microplate reader (BioTek) using excitation and
emission wavelengths of 360 and 460 nm, respectively. The Km and Vmax were
calculated by fitting the data to the appropriate Michaelis-Menten equations by using
nonlinear regression in the GraphPad Prism 4 software.
Virus Transmission Experiments in Ferrets
The animal work with the pandemic H1N1/2009 influenza viruses was performed
in an animal biosafety level 3+ (ABSL3+) laboratory approved by the U.S. Department
of Agriculture. The animal work with seasonal H1N1 influenza viruses was conducted in
ABSL2+ laboratory under applicable laws and guidelines and after approval from the St.
Jude Children’s Research Hospital Animal Care and Use Committee. The ferrets for the
pandemic H1N1 virus study were were obtained from the ferret breeding program at St.
Jude Children’s Research Hospital. The ferrets for the seasonal H1N1 virus study were
obtained from Triple F farm. All ferrets were 4-5 months of age and were sero-negative
for contemporary influenza A H1N1 and H3N2 viruses and for influenza B viruses.
Ferrets were firstly housed in the isolators in and monitored for 3-5 days to establish
baseline body temperature and overall health. Donor ferrets were initially housed
separately from contact ferrets.
The experiment settings were slightly different between the studies for pandemic
and seasonal H1N1 viruses. For the study of pandemic viruses, one donor ferrets were
lightly anesthetized with isoflurane and inoculated with 106 TCID50 of each of the
pandemic H1N1 viruses in 1.0 ml sterile PBS respectively. One donor ferret was
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inoculated with 106 TCID50 of a mixture of A/DM/524/09 and A/DM/528/09 viruses (1:1
infectivity ratio). After the donor ferrets were confirmed to shed virus on day 2 p.i. by the
Directigen Flu A+B quick test (BD, Franklin Lakes, NJ), each was then housed with 2
naïve direct-contact ferrets in the same cage. Two additional recipient ferrets were placed
in an adjacent cage isolated from the donor’s cage by a two layers of wire mesh (~5 cm
apart) that prevented physical contact but allowed the passage of respiratory droplets.
Borazine gun (Zero Toys, Concord, MA ) tested that the airflow was non-directional
inside the isolator. Thus, the transmission setting was 1 donor + 2 direct-contact + 2
respiratory-droplet recipient ferrets for each tested pandemic virus.
For the study of seasonal viruses, three donor ferrets were inoculated with 105
TCID50 each of the seasonal H1N1 viruses in 1.0 ml sterile PBS respectively as the
results listed. Then at day 1p.i, each was then housed with 1 naïve direct-contact ferrets in
the same cages. One additional naïve ferret was placed in an adjacent cage separated by
double layers of perforated dividers (~5cm apart) for the purpose of respiratory-droplet
transmission. The cages were oriented to direct the airflow from the donor cage side to
the respiratory-droplet recipient cage side. Thus the transmission setting was 3 replicates
of 1 donor + 1 direct-contact + 1 respiratory-droplet recipient ferret for each virus. For
both studies, Ferret nasal wash samples were collected at day1 p.i and the following
every other day from day 2 p.i for 14 days. Ferret weight, temperature and other clinical
signs were recorded daily for 21 days. Body temperature was measured by subcutaneous
implantable temperature transponders (Bio Medic Data Systems Inc, Seaford, DE).
Collection and Titration of Nasal Wash Samples
Nasal washes were collected from donor and recipient ferrets on day 1, 2, 4, 6, 8,
10, 12, and 14 p.i. by flushing ferret both nostrils with 1.0 ml PBS, and TCID50 titers
were determined in MDCK cells. Inflammatory cell counts were determined for the
pandemic virus study. Briefly, the nasal washes were centrifuged at 2000 rpm for 5 min.
The pellet was resuspended in PBS, and the total cell number was counted in a
hemacytometer under light microscopy. Inflammation was defined as a cell count  10
times the baseline count which was determined before the inoculation or exposure.
Serologic Tests
Serum samples were collected from ferrets 3 weeks after virus inoculation, treated
with receptor-destroying enzyme, heat-inactivated at 56 °C for 30 min, and tested by HI
assay with 0.5% packed Turkey red blood cells (TRBC).
Quantitative Single Nucleotide Polymorphism Assay
The quantitative single nucleotide polymorphism (SNP) assay was performed to
determine the proportion of wild-type or H275Y mutant viruses in mixed sample for the
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pandemic virus study as described previously (138), with slight modification. Briefly, an
NA fragment (nucleotide 673 to 1034) containing the codon at NA 275 position was
amplified by RT-PCR. Single nucleotide primer extension was performed using a
SNaPshot kit (ABI) per the manufacturer’s protocol. A extension probe was used to
detect the first nucleotide of NA 275 codon. After the SNaPshot reaction, the product was
analyzed by ABI 3730xl capillary electrophoresis instrument (ABI) per the
manufacturer’s protocol. Data were analyzed by using ABI GeneMapper software.
Statistical Analysis
The unpaired t-test or analysis of variance (ANOVA) was used for all
comparisons, if the significance was indicated in the result description, then p<0.05.
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